{"doc_id": "snmmi__v00000000", "chunk_id": "000000", "text": "# SNMMI", "section": "SNMMI", "page_from": null, "page_to": null, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "4ac210822b5ccad68a28661021c974ce158ff7217d9def770d83566e8e677c12"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000001", "text": "P R O C E D U R E S T A N D A R D\nSNMMI Procedure Standard/EANM Practice Guideline for\nBrain [18F]FDG PET Imaging, Version 2.0\nJavier Arbizu1, Silvia Morbelli2,3, Satoshi Minoshima4, Henryk Barthel5, Philip Kuo6, Donatienne Van Weehaeghe7,\nNeil Horner8, Patrick M. Colletti9, and Eric Guedj10\n1Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain; 2Nuclear Medicine Unit,\nCitta’della Scenza e della Salute di Torino, Turin, Italy; 3Department of Medical Sciences, University of Turin, Turin, Italy; 4Department\nof Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah; 5Department of Nuclear Medicine, Leipzig University\nMedical Centre, Leipzig, Germany; 6University of Arizona, Tucson, Arizona; 7Department of Radiology and Nuclear Medicine, Ghent\nUniversity Hospital, Ghent, Belgium; 8Atlantic Health System, Morristown, New Jersey, and Icahn School of Medicine at Mount Sinai,\nNew York, New York; 9Department of Radiology and Nuclear Medicine, University of Southern California, Los Angeles, California;\nand 10APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a2e4ba3f7663e15283c5a22cc932dcce01492f23fbfddc72bfc1d7bcadc52e95"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000002", "text": "and 10APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille\nUniversity, Marseille, France\nPREAMBLE\nThe Society of Nuclear Medicine and Molecular Imaging (SNMMI) is\nan international scientiﬁc and professional organization founded in\n1954 to promote the science, technology, and practical application of\nnuclear medicine. The European Association of Nuclear Medicine\n(EANM) is a professional nonproﬁt medical association that facilitates\ncommunication worldwide between individuals pursuing clinical and\nresearch excellence in nuclear medicine. The EANM was founded in\n1985. The EANM was founded in 1985. SNMMI and EANM members\nare physicians, technologists, and scientists specializing in the research\nand practice of nuclear medicine.\nThe SNMMI and EANM will periodically deﬁne new guidelines for\nnuclear medicine practice to help advance the science of nuclear medi-\ncine and to improve the quality of service to patients throughout the\nworld. Existing practice guidelines will be reviewed for revision or\nrenewal, as appropriate, on their ﬁfth anniversary or sooner, if indicated.", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "cb4b82b1db16283c0fcd1534768da9e8385c670761d2e6c6e60bf0d26244ccb8"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000003", "text": "world. Existing practice guidelines will be reviewed for revision or\nrenewal, as appropriate, on their ﬁfth anniversary or sooner, if indicated.\nEach practice guideline, representing a policy statement by the\nSNMMI/EANM, has undergone a thorough consensus process in\nwhich it has been subjected to extensive review. The SNMMI and\nEANM recognize that the safe and effective use of diagnostic nuclear\nmedicine imaging requires speciﬁc training, skills, and techniques, as\ndescribed in each document. Reproduction or modiﬁcation of the\npublished practice guideline by those entities not providing these ser-\nvices is not authorized.\nThese guidelines are an educational tool designed to assist practi-\ntioners in providing appropriate care for patients. They are not inﬂexi-\nble rules or requirements of practice and are not intended, nor should\nthey be used, to establish a legal standard of care. For these reasons\nand those set forth below, both the SNMMI and the EANM caution\nagainst the use of these guidelines in litigation in which the clinical\ndecisions of a practitioner are called into question.\nThe ultimate judgment regarding the propriety of any speciﬁc pro-", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "398f190d7a7b494d94d6af2f4efb6d039701dae558c15ebea27963cdb92b5a40"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000004", "text": "against the use of these guidelines in litigation in which the clinical\ndecisions of a practitioner are called into question.\nThe ultimate judgment regarding the propriety of any speciﬁc pro-\ncedure or course of action must be made by the physician or medical\nphysicist in light of all the circumstances presented. Thus, there is no\nimplication that an approach differing from the guidelines, standing\nalone, is below the standard of care. To the contrary, a conscientious\npractitioner may responsibly adopt a course of action different from\nthat set forth in the guidelines when, in the reasonable judgment of the\npractitioner, such course of action is indicated by the condition of the\npatient, limitations of available resources, or advances in knowledge\nor technology subsequent to publication of the guidelines.\nThe practice of medicine includes both the art and the science of\nthe prevention, diagnosis, alleviation, and treatment of disease. The\nvariety and complexity of human conditions make it impossible to\nalways reach the most appropriate diagnosis or to predict with cer-\ntainty a particular response to treatment.\nTherefore, it should be recognized that adherence to these guide-", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b0f913cdd21c34aed38f6e688ca0386cfea09bf7e1e2cb03be39a4f69b5afc9d"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000005", "text": "always reach the most appropriate diagnosis or to predict with cer-\ntainty a particular response to treatment.\nTherefore, it should be recognized that adherence to these guide-\nlines will not ensure an accurate diagnosis or a successful outcome.\nAll that should be expected is that the practitioner will follow a rea-\nsonable course of action based on current knowledge, available\nresources, and the needs of the patient to deliver effective and safe\nmedical care. The sole purpose of these guidelines is to assist practi-\ntioners in achieving this objective.\nI. INTRODUCTION\nThe purpose of this document is to provide nuclear medicine\npractitioners in making recommendations, performing, interpret-\ning, and reporting results of PET imaging of the brain using\n2-[18F]ﬂuoro-2-deoxy-D-glucose ([18F]FDG).\nNuclear medicine is the medical specialty that uses the tracer\nprinciple, most often with radiopharmaceuticals, to evaluate molec-\nular, metabolic, physiologic, and pathologic conditions of the body\nfor the purposes of diagnosis, therapy, and research.\nThe combination of anatomic information from other modalities\nmay complement the information from tracers, providing more", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e22e4501359f746928e75a008c811c27028e03e861b42b391c45bac86cd34462"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000006", "text": "for the purposes of diagnosis, therapy, and research.\nThe combination of anatomic information from other modalities\nmay complement the information from tracers, providing more\ninformation than the sum of the two separately.\nThe present document considers the work of previous procedure\nguidelines organizations such as the Society of Nuclear Medicine\nMolecular Imaging (SNMMI) Brain Imaging Council [Alan D.\nWaxman, MD; Karl Herholz, MD; David H. Lewis, MD; Peter\nHerscovitch, MD; Satoshi Minoshima, MD; PhD, Masanori Ichise,\nMD; Alexander E. Drzezga, MD; Michael D. Devous, Sr., PhD;\nReceived Sep. 5, 2024; revision accepted Sep. 5, 2024.\nFor correspondence or reprints, contact Javier Arbizu (atpacientecun@\nunav.es).\nPublished online Oct. 17, 2024.\nImmediate Open Access: Creative Commons Attribution 4.0 International\nLicense (CC BY) allows users to share and adapt with attribution, excluding\nmaterials credited to previous publications. License: https://creativecommons.\norg/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.\nCOPYRIGHT \u0001 2024 by the Society of Nuclear Medicine and Molecular Imaging.\nDOI: 10.2967/jnumed.124.268754\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n1", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e6dfe62479f829e7d4682117e79ac723f6977eb3a2df6df43515b9bc6f7bcda2"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000007", "text": "COPYRIGHT \u0001 2024 by the Society of Nuclear Medicine and Molecular Imaging.\nDOI: 10.2967/jnumed.124.268754\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n1\n\nJournal of Nuclear Medicine, published on October 17, 2024 as doi:10.2967/jnumed.124.268754", "section": "P R O C E D U R E S T A N D A R D", "page_from": 1, "page_to": 1, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e95627793c22bb73130905399682e48c20dfc5e60fbedabf506896d4f2b4b197"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000008", "text": "James M. Mountz, MD, PhD] (1) and the European Association of\nNuclear Medicine (EANM) Neuroimaging Committee (2).\nThese new practice guidelines incorporate advances in PET tech-\nnology such as digital PET and hybrid PET/MR systems, dedicated\nbrain PET systems, advances in individual PET semiquantitative\nanalysis, and current broadening clinical indications (e.g., for\nencephalitis and brain lymphoma). Further insight has also become\navailable about hyperglycemia effects in patients who undergo\nbrain [18F]FDG PET. Accordingly, the patient preparation proce-\ndure has been updated. Finally, most typical brain patterns of meta-\nbolic changes are summarized for neurodegenerative diseases.\nThe information provided should be taken in the context of local\nconditions and regulations.\nII. GOALS\nThe goal of this guideline is to achieve a high-quality standard\nof [18F]FDG brain imaging, to further increase the diagnostic\nimpact of this technique in neurologic, neurosurgical, and psychi-\natric practice.\nIII. DEFINITIONS\nSee also the SNMMI Guideline for General Imaging.\nIn the brain, glucose metabolism provides approximately 95%\nof adenosine triphosphate required for brain function. Under phys-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2390a58cd3e8c40d2ea84d614702734a00ad7e1e6808714f3e1145097806449c"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000009", "text": "III. DEFINITIONS\nSee also the SNMMI Guideline for General Imaging.\nIn the brain, glucose metabolism provides approximately 95%\nof adenosine triphosphate required for brain function. Under phys-\niologic conditions, glucose metabolism is tightly coupled to neuro-\nnal activity. [18F]FDG is suitable for imaging regional cerebral\nglucose consumption with PET since it accumulates in neuronal\ntissue depending on facilitated transport of glucose via glucose\ntransporters and hexokinase-mediated phosphorylation, as well as\nthe functional interactions between astrocytes and neurons (3).\nTherefore, changes in neuronal activity induced by disease are\nreﬂected in an alteration of glucose metabolism. Also, inﬂamma-\ntory processes and malignant tumors exhibit increased glucose\nmetabolism. [18F]FDG PET is currently the most accurate in vivo\nmethod for the investigation of regional human brain glucose\nmetabolism in health and disease states.\nThe clinical use of [18F]FDG can be regarded as established for\nseveral diagnostic questions in neurology, neurosurgery, and psy-\nchiatry. This information is often complementary to the anatomic\ndetail provided by structural imaging techniques such as CT or", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "d0f501165122d3b25cf80a66bed1923f41bf68c3c23afe3ccffbb0bc5ab9690b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000010", "text": "several diagnostic questions in neurology, neurosurgery, and psy-\nchiatry. This information is often complementary to the anatomic\ndetail provided by structural imaging techniques such as CT or\nMRI. However, functional impairment often precedes structural\nchanges and may also exist alone.\nIV. COMMON CLINICAL INDICATIONS\nThe following clinical indications especially integrate the EANM\nand SNMMI recommendations for the use of brain [18F]FDG PET (4).\nCommon indications for brain PET imaging using [18F]FDG\ninclude, but are not limited to, the following:\nA. Common Indications\n1. Cognitive Impairment and Dementia. In neurodegenerative\ndisorders such as Alzheimer disease (AD), changes in synaptic activ-\nity occur early in the course of the disease, when macrostructural\nbrain changes cannot yet be detected. Furthermore, tau pathology was\nshown to mirror brain hypometabolism and clinical symptoms (5). In\nthis line, the hypometabolism signiﬁcantly exceeded atrophy in most\naltered brain regions, which is however not the case in the hippocam-\npus, suggesting that for such structures, synaptic compensatory mech-\nanisms may be taking place, maintaining neuronal activity in spite of", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "27eabd0be577ca4be98cca36006af402211a344073968d989aba2b781942ed4a"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000011", "text": "pus, suggesting that for such structures, synaptic compensatory mech-\nanisms may be taking place, maintaining neuronal activity in spite of\nstructural alteration (6), especially in younger patients. Despite its\nrelatively small dimension, hippocampal hypometabolism is neverthe-\nless more evident in late-onset AD (7). Additionally, new categories\nfor neurodegenerative disorders have been recognized including of\nthe transactive response DNA binding protein of 43 kDa (TDP-43)\nproteinopathy (LATE), primary age-related tauopathy, and argyro-\nphilic grain disease, in conjunction with hippocampus sclerosis,\nwhich need to be incorporated into the interpretation of [18F]FDG\nPET images (8). The recognition of LATE on [18F]FDG PET is par-\nticularly important as there is currently no imaging biomarker of\nTDP-43, and AD and LATE pathologies overlap signiﬁcantly in\nelderly patients.\nIn AD, [18F]FDG PET is viewed as a marker of neurodegeneration\n(N) and progression, and currently included—along with hippocam-\npal volume measured with MRI—in the A/T/N, classiﬁcation scheme\nwith amyloid-b (A) and tau (T) (9,10). A recent study suggests that", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "59e11c132af0713ceaee19d4512ec2d1c36416a4665e501c34b7784d052ec773"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000012", "text": "(N) and progression, and currently included—along with hippocam-\npal volume measured with MRI—in the A/T/N, classiﬁcation scheme\nwith amyloid-b (A) and tau (T) (9,10). A recent study suggests that\n[18F]FDG PET is an independent biomarker to predict AD conver-\nsion in patients with mild cognitive impairment (MCI) along with\namyloid-b and tau, independent of hippocampal volume (11) and of\namyloid PET status (12,13). In the diagnostic work-up of patients\nwith suspected AD dementia, the use of [18F]FDG PET is comple-\nmentary to A and T biomarkers: amyloid PET and cerebrospinal ﬂuid\n(CSF) Ab42 for amyloid biomarkers, and CSF phosphorylated tau\nand tau PET for tau biomarkers (14). [18F]FDG PET is recommended\nto support early diagnosis of AD in MCI (15), early diagnosis of\ndementia with Lewy bodies (DLB) (in addition to presynaptic dopa-\nminergic imaging which usually is more accurate in this indication)\n(16), and frontotemporal lobar degeneration (FTLD) (17). [18F]FDG\nPET is also recommended to support the differential diagnosis\nbetween AD and FTLD, between AD and DLB, between FTLD and\nDLB, between AD and vascular dementia when clinical and MRI", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "4487c73cfb4f4fe7de83d759ab135bb055cd53dbc7772a65b52c029a8cf88b20"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000013", "text": "PET is also recommended to support the differential diagnosis\nbetween AD and FTLD, between AD and DLB, between FTLD and\nDLB, between AD and vascular dementia when clinical and MRI\ndata are inconclusive, and between differential diagnosis within neu-\nrodegenerative parkinsonian syndromes associated with dementia\n(15,18–20). In the framework of cognitive impairment work-up, a\nrecent consensus algorithm has been proposed on suitable indications\nof [18F]FDG PET, especially emphasizing its great value as a ﬁrst-\nline evaluation when a non-AD disorder is clinically suspected\n(14,21). Typical topographic patterns of relative hypometabolism\nassociated with AD, FTLD, and DLB are summarized in the EANM\nprocedure guidelines for brain PET imaging using [18F]FDG (2). Pat-\nterns of hypometabolism tend to mirror clinical presentations and\nmight also help to support diagnostic work-up of atypical AD in the\nframework of posterior cortical atrophy (22–24) and primary progres-\nsive aphasia (25). For sensitivity, speciﬁcity, and positive and nega-\ntive predictive value of [18F]FDG PET in this framework, the reader\nis referred to the EANM/European Association of Neurology recom-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "150fbaed7c54070db306d0700a1527539e63671dab02c04fd0c6fbf77a17d65a"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000014", "text": "tive predictive value of [18F]FDG PET in this framework, the reader\nis referred to the EANM/European Association of Neurology recom-\nmendations and to the original publications (4). Beyond the differen-\ntial diagnosis with vascular dementia, [18F]FDG PET can also be\nused to help distinguish between cognitive impairment of degenera-\ntive diseases from nondegenerative origin, such as in traumatic brain\ninjury (in correlation to MRI using PET/MRI device or fusion (26)),\nidiopathic normal-pressure hydrocephalus (showing striatal hypome-\ntabolism with preserved cortical metabolism) (27), postacute infection\nsyndrome (showing limbic/paralimbic, brain stem, and cerebellar\nhypometabolisms) (28–31), or depression. For the latter, studies\nreport mild to moderate cortical resting state relative hypometabolism\nin [18F]FDG PET involving the frontal, temporal, insular, and cingu-\nlate areas, especially including the limbic areas, as well as the basal\nganglia, in relation with the clinical severity and the therapeutic\nresponse (32–34), as well as possible pharmacologic interferences\nmostly in group analyses: these possible subtle brain abnormalities", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "c432911347273ba5916023faf5924ebe50bad78b19a52d64df0f19bbdec6ca0e"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000015", "text": "response (32–34), as well as possible pharmacologic interferences\nmostly in group analyses: these possible subtle brain abnormalities\nassociated with depression at individual level usually do not limit the\n2\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 2, "page_to": 2, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "97acc73a88d9f342b88504a67f3b6e6cb3ce2004ebdd27e0baf329d54d51d1c1"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000016", "text": "differential diagnosis with neurodegenerative diseases. Interestingly, a\nnormal [18F]FDG PET scan has a relevant negative predictive value\nat the MCI stage, with less than 10% of patients progressing to\ndegenerative dementia over 3y (35).\n2. Movement Disorders and Parkinsonian Syndromes. [18F]FDG\nPET can be used for the differential diagnosis between Parkinson\ndisease (PD) and atypical parkinsonian syndromes such as progres-\nsive supranuclear palsy (PSP), multiple system atrophy (MSA), cor-\nticobasal syndrome, and the already mentioned DLB (36,37).\nTypical topographic patterns of cortical and subcortical changes in\nglucose metabolism of parkinsonian conditions have been described\nin neurodegenerative parkinsonism based on qualitative interpreta-\ntion and semiquantitative analysis using voxel-based analysis or\nprincipal component analyses with estimation of spatial covariance\npatterns (i.e., metabolic connectivity) (38–45). PD patients exhibit\nrelative hypermetabolism in basal ganglia, motor cortex, and cerebel-\nlar vermis and variable hypometabolism in cortical associative areas\n(46). However, when PD patients are scanned under dopaminergic", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "203cacacca4233c7fd6dc4e1761efa7e6d75dfbd9cb6270ccd78a3af6a7bbbd1"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000017", "text": "lar vermis and variable hypometabolism in cortical associative areas\n(46). However, when PD patients are scanned under dopaminergic\ntreatment, relative hypermetabolism of cerebellar vermis, basal gan-\nglia, and motor cortex might be reduced (47). Cortical relative hypo-\nmetabolism in temporo-occipital and parietal regions has also been\ndescribed in PD MCI or PD patients that develop PD with dementia\nat follow-up (38). Interestingly, patients with idiopathic rapid eye\nmovement sleep behavior disorder, a prodromal stage of PD, DLB,\nor MSA, present a brain glucose metabolism pattern partially over-\nlapped with the PD-related pattern (48). Moreover, a brain meta-\nbolic pattern reﬂecting the risk of phenotypic conversion from\nidiopathic rapid eye movement sleep behavior disorder to an overt\na-synucleinopathy has been demonstrated (49).\nUnlike PD, atypical parkinsonian conditions exhibit a neurode-\ngeneration of subcortical areas like basal ganglia, mesencephalon,\nor cerebellum with a consequent decrease of synaptic activity in\n[18F]FDG PET (43,50). Typical topographic patterns of relative\nhypo- and hypermetabolism associated with PD, PSP, MSA, and", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "d17b77949f2b7fbf578f463735ca7e19b107365b4f509919538102d2543e3e33"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000018", "text": "or cerebellum with a consequent decrease of synaptic activity in\n[18F]FDG PET (43,50). Typical topographic patterns of relative\nhypo- and hypermetabolism associated with PD, PSP, MSA, and\nCBD are summarized in the EANM procedure guidelines for brain\nPET imaging using [18F]FDG (2). PSP is the second most frequent\ncause of neurodegenerative parkinsonian syndrome after PD or DLB,\nand the related pattern is expressed in the Richardson syndrome\nvariant as well as other less common PSP variants (43). Moreover,\n[18F]FDG PET is recommended to support clinical diagnosis of\nPSP and included as a prognostic biomarker (51,52).\n3. Other Neurodegenerative Motor Diseases. The clinical use\nof [18F]FDG PET as biomarker has been also proposed on other\nneurodegenerative diseases, such as amyotrophic lateral sclerosis\n(ALS) and Huntington disease (HD) (53). In ALS, the brain meta-\nbolic pattern consists of hypometabolism in the primary, pre-, and\nsupplementary motor cortices extending to the frontoparietal cortex\nand relative hypermetabolism in the cerebellum and brain stem.\nMetabolism in the medial temporal cortex can range between hyper-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "8400155a241d90fe604abaf52c15ac6ee937398c78696411afa46768e8cb001e"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000019", "text": "supplementary motor cortices extending to the frontoparietal cortex\nand relative hypermetabolism in the cerebellum and brain stem.\nMetabolism in the medial temporal cortex can range between hyper-\nand hypometabolism depending on whether the patient has associated\nfrontotemporal dementia. There is a continuum between ALS and\nfrontotemporal dementia in which 50% of patients have minor cogni-\ntive and behavioral changes, whereas 10%–15% have overt fronto-\ntemporal dementia (54). In the clinical setting, [18F]FDG brain PET\nhas a prognostic value as patients with frontotemporal hypometabo-\nlism have a worse prognosis because of associated frontotemporal\ndementia. Although, the metabolic pattern is able to discriminate\npatients from controls with an accuracy higher than 90% (55–57), the\ndiagnostic value is limited as the brain metabolic pattern is similar\nbetween diseases that mimic the symptoms of ALS (ALS-mimics)\nand ALS patients (58). In HD, [18F]FDG PET has only limited\nclinical value; however, HD patients with atypical (i.e., behavioral/\npsychiatric) presentations might be submitted to [18F]FDG PET in\nthe suspect of other diseases, and the nuclear medicine physician", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "454bbdd23711ddcddc2970127dfde5582278d95737f7c502f7cd4051ce20758f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000020", "text": "psychiatric) presentations might be submitted to [18F]FDG PET in\nthe suspect of other diseases, and the nuclear medicine physician\nshould be able to recognize a peculiar pattern of hypometabolism\nassociated with HD. It has been described that the striatal hypometa-\nbolism present in HD may identify presymptomatic mutation carriers\nwho will develop clinical HD (59–63). Besides striatal hypometabo-\nlism, HD is associated with a decreased cortical metabolism and an\nincreased thalamic, occipital, and cerebellar metabolism (60). The\nrespective hypo- and hypermetabolism gradually increases during dis-\nease progression and aids selection of patients for clinical trials (64).\n4. Epilepsy. The common indication is the presurgical evalua-\ntion of focal pharmaco-resistant epilepsy in adults and children to\nidentify the epileptogenic zone using interictal injection (65–70).\nWith a better spatial resolution, [18F]FDG PET has also higher\nsensitivity than interictal perfusion SPECT, especially in temporal\nlobe epilepsy (84% vs. 66% in a metaanalysis study) (71). Uncoupling\nof blood ﬂow and metabolism is moreover suspected in epilepsy, with", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "63d329a1b9ad131692ed36ed7ef0553eeed14bc119e79d31dc0d99562eb72722"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000021", "text": "lobe epilepsy (84% vs. 66% in a metaanalysis study) (71). Uncoupling\nof blood ﬂow and metabolism is moreover suspected in epilepsy, with\nmore pronounced cerebral reduction in glucose metabolism than in\nperfusion. Of note, the interictal brain PET hypometabolism corre-\nsponds with the entire irritative zone (i.e., the epileptogenic zone and\nsubsequent neural networks involved in the generation of interictal\nparoxysms). In this line, extension of hypometabolism to areas beyond\nthe temporal lobe is often found in patients with focal epilepsy, but\nnevertheless with a great correlation to clinical presentations and\nstereo-electroencephalogram (EEG) (66,67). Performance is lower in\nextratemporal lobe epilepsy with identiﬁcation of the epileptogenic\nzone in 38%–67% of cases (65). [18F]FDG PET is of particular inter-\nest in suspected focal cortical dysplasia, also in children, and espe-\ncially in case of (apparent) negative MRI (67). Correlation to brain\nMRI using PET/MR device or image fusion techniques is particularly\nimportant in this framework to identify initially unknown lesions.\nInterestingly, clinical outcome of cases with positive PET and nega-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "06db5cb51626be7919397d042431f7c66941b34fdf0976571c9af78e42a2f08a"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000022", "text": "important in this framework to identify initially unknown lesions.\nInterestingly, clinical outcome of cases with positive PET and nega-\ntive MRI is similar to those with positive MRI (72,73). Finally,\n[18F]FDG PET has good prognostic value for postsurgical outcome,\nespecially in case of limited hypometabolism extent (66,74–76), and\nprovides a prognostic value on cognition with more limited hypometa-\nbolism associated with a better postoperative cognitive status (77,78).\n5. Encephalitis. Encephalitis includes autoimmune encephalitis\n(AE) and paraneoplastic limbic encephalitis and infectious and\npostinfectious encephalitis, as well frontier presentations (e.g.,\nMorvan syndrome (79)) and differential diagnosis of inﬂammatory\nencephalopathies (e.g., neuro-lupus (80); see Appendix of (81) for\nthe whole spectrum of these disorders). With a higher sensitivity,\n[18F]FDG PET is especially relevant in patients with negative or\ninconclusive MRI (82–85), both for adults and children (86). A\nrecent systematic review and metaanalysis conﬁrms a sensitivity of\n80%–90% of [18F]FDG PET with a typical pattern associating\nglobal hypometabolism to striatal and limbic relative hypermetabo-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a198e231b991c233ff4f521fce4adff49eb1abb1095c2c46b200f3577f9d4e3f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000023", "text": "recent systematic review and metaanalysis conﬁrms a sensitivity of\n80%–90% of [18F]FDG PET with a typical pattern associating\nglobal hypometabolism to striatal and limbic relative hypermetabo-\nlism (87), with also a speciﬁcity of 82% against MCI (88). Medial\ntemporal changes have been preferentially associated with autoanti-\nbodies against intracellular antigens (89). This metabolic proﬁle is\nalso used in the follow-up to evaluate therapeutic efﬁcacy, whereas\nwhole-body PET is performed to identify cancer in paraneoplastic\nsyndromes or systemic inﬂammatory localizations (90).\n6. Neurooncology. Because of the high physiologic uptake of\n[18F]FDG in normal brain gray matter and variable uptake by\ninﬂammatory lesions, [18F]FDG PET has a more limited impact\nthan amino-acid PET—when available—in the imaging of gliomas\n(91). Better contrast between tumor and normal brain tissue as\nwell between gray and white matter can be obtained with a longer\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n3", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 3, "page_to": 3, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7a8113df1e67a224e83e87acc9986a62ab777234d1fffda8ff0a5b8065775583"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000024", "text": "time interval from FDG administration to data acquisition (e.g.,\n60 min up to several hours for tumors) (92). A standardized acqui-\nsition protocol is nevertheless recommended with a ﬁxed time for\nstarting the acquisition to improve the comparability from different\npatients or repeated scans. [18F]FDG PET can be used in the diag-\nnosis of lymphoma, since most primary central nervous system\nlymphoma (PCNSL) lesions are highly [18F]FDG-avid, with\nhomogeneous uptake, and also in the differential diagnosis of non-\nmalignant lesions in patients with AIDS (and particularly Toxo-\nplasma infection) (93). The diagnostic accuracy of pretreatment\nbrain [18F]FDG PET is high in PCNSL with pooled sensitivity,\nspeciﬁcity, positive predictive value, and negative predictive value\nhigher than 84% (94), with an uptake predictive of the therapeutic\nresponse (95). PET also contributes to the evaluation of whole-\nbody extension of the lymphoma with less than 5% of false posi-\ntives in another recent metaanalysis (96). Interestingly, amino-acid\nPET has not demonstrated an additional value over [18F]FDG PET\nin PCNSL (97). However, in patients with gliomas, the role of", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "bf6e4c0c7efa773c3a3e2dbdebb8191c063627c37182ff0dd5a134fce73241ce"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000025", "text": "tives in another recent metaanalysis (96). Interestingly, amino-acid\nPET has not demonstrated an additional value over [18F]FDG PET\nin PCNSL (97). However, in patients with gliomas, the role of\n[18F]FDG PET is limited as discussed in dedicated procedural\nguidelines (98). If amino-acid PET is not available, [18F]FDG PET\ncan be used at diagnosis, with increasing [18F]FDG uptake corre-\nlated to higher tumor grade and poorer prognosis (99), despite\noverlap between grade I/II and grade III/IV gliomas, with also a\nprognostic value on survival at recurrence (100). [18F]FDG PET\nmay be used to distinguish radiation necrosis from recurrent tumor,\nwith moderate additional value in comparison to MRI, usually at\nleast 6 to 8 wk after radiation therapy, with a pooled sensitivity and\nspeciﬁcity of 84% on a recent metaanalysis (91,98,101,102) for gli-\nomas and for brain metastases with reported sensitivities and speci-\nﬁcities ranging from 50% to nearly 100% (103).\nB. Relative Contraindications and Limitations\nThere is no signiﬁcant contraindication associated with intrave-\nnous injection of [18F]FDG, but cautions should be paid to the fol-\nlowing conditions.", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7c87a3d6602b6e9080499d22ad66acb59e10646f6d45de7818ca9f5c81e7afd8"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000026", "text": "B. Relative Contraindications and Limitations\nThere is no signiﬁcant contraindication associated with intrave-\nnous injection of [18F]FDG, but cautions should be paid to the fol-\nlowing conditions.\n1. Patient Safety. In the case of PET/MRI, patient safety informa-\ntion concerning magnetic ﬁeld should be carefully screened before\nMRI (including the presence of devices potentially not compatible,\nsuch as pacemakers, neurostimulators, cochlear implants, non–\nMRI-compatible metal implants, pumps, etc.; in case of doubt for\nocular metal pieces, a low dose x-ray can be performed).\n2. Pregnancy. For any diagnostic procedure in a woman patient\nknown or suspected to be pregnant, a critical decision is necessary\nto assess whether the beneﬁts weigh against the possible harm.\n3. Breast Feeding. Women should interrupt breast feeding at\nleast for the ﬁrst hours after a scan per the guidance of the Nuclear\nRegulatory Commission Advisory Committee on the Medical Use\nof Isotopes (ACMUI) in the United States, although in many Euro-\npean countries, 24 h is recommended.\n4. Lack of Cooperation or Inability to Tolerate. Claustrophobia\nand, most importantly, obesity can also be an obvious limitation,", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "c9560a6a152031f0300b757486590935b22615ee1045ecea0a7e0197a744e084"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000027", "text": "pean countries, 24 h is recommended.\n4. Lack of Cooperation or Inability to Tolerate. Claustrophobia\nand, most importantly, obesity can also be an obvious limitation,\nespecially for PET/MR.\n5. Uncontrollable Hyperglycemia. Hyperglycemia can be a\nlimitation because of the inadequate statistical image quality and\ngray-matter to white-matter contrast.\nV. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL\nA. Physician\nAll nuclear medicine examinations should be performed under\nthe supervision of and interpreted by a physician certiﬁed in\nnuclear medicine or nuclear radiology by the American Board of\nNuclear Medicine or the national equivalent. The physician should\nmaintain their certiﬁcation in the ﬁeld of nuclear medicine.\nB. Medical Physicist\nThe medical physicist should be able to practice independently\none or more of the subﬁelds of medical physics. National Regula-\ntories and SNMMI consider certiﬁcation (by the American Board\nof Science in Nuclear Medicine or by the American Board of\nRadiology, or the equivalent) and continuing education in the\nappropriate subﬁeld(s) to demonstrate an individual is competent.\nC. Technologist", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "5837bffbe088a84bf73a29c1d17c149b7478b42c201a4dfaa2371c0bfa991f32"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000028", "text": "Radiology, or the equivalent) and continuing education in the\nappropriate subﬁeld(s) to demonstrate an individual is competent.\nC. Technologist\nAll nuclear medicine examinations should be performed by a\nnuclear medicine technologist that is registered and certiﬁed in\nnuclear medicine by the Nuclear Medicine Technology Certiﬁca-\ntion Board or national equivalent. The nuclear medicine technolo-\ngist works under the supervision of the physician.\nVI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION\nSee also the SNMMI Guideline for General Imaging.\nA. Nuclear Medicine Study Request\n1. Information Relevant for the Procedure.\na. History of diseases, especially neurologic and psychiatric\ndisorders, and current neurologic and psychiatric status\nincluding clinical test results, surgery, radiation, or trauma\nof the brain.\nb. History of diabetes and knowledge of patient’s fasting\nstate.\nc. Patients’ ability to lie still for 15 min to 1 h. If sedation is\nrequired, it should be performed as late as possible. The\nintention should be to administer [18F]FDG at least 30 to\n40 min before the sedation.\nd. Information about recent structural imaging studies (CT,", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "3e2bbd356db37456b68379355a57ea030261787eab7c7c437e1e43b34f8b64fb"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000029", "text": "intention should be to administer [18F]FDG at least 30 to\n40 min before the sedation.\nd. Information about recent structural imaging studies (CT,\nMRI), prior PET (FDG, amyloid, or tau imaging), or SPECT\nbrain images, ﬂuid biomarkers (CSF, plasma), blood bio-\nchemistry indicative of metabolic dysfunction or systemic\ndisease (e.g., hepatic, thyroid, renal), as well as about func-\ntional brain explorations (EEG, neuropsychology) in speci-\nﬁc conditions.\ne. Ongoing necessary therapies are allowed but current medi-\ncations (and timing of their last administration) must be\nrecorded. This information (including duration and dos-\nage) is particularly relevant for sedatives, psychotropic\npharmaceuticals, antiseizure medication, and corticoster-\noids. Possible effects of these medications on regional\nmetabolic rate of glucose consumption (rCMRglc) have\nbeen suggested (104–106), but such effects on diagnostic\naccuracy of [18F]FDG PET have not been addressed\nsystematically.\nUse and dosage of corticosteroids might be particularly relevant\nfor emerging indications of brain [18F]FDG PET such as AE and\nPCNSL. In whole-body [18F]FDG PET, possible false-negative", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "d467074f8615b236e32ba3047a4daa9e02a2a998ec8e04fc6f5d7d4ac5b6b937"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000030", "text": "Use and dosage of corticosteroids might be particularly relevant\nfor emerging indications of brain [18F]FDG PET such as AE and\nPCNSL. In whole-body [18F]FDG PET, possible false-negative\nresults are well known for inﬂammatory and autoimmune diseases\ntreated with corticosteroids (107,108). For brain [18F]FDG PET,\nand whenever clinically possible, it is also advised to scan patients\nbefore starting (or in any case as soon as possible after initiating)\nsteroid treatment in case of both AE and PCNSL.\nRegarding discontinuation of abuse drugs, it should be noted\nthat reports are also available about the effects of early abstinence\non regional brain metabolism. For example, a shift in cortical–\nsubcortical metabolic balance has been reported during early\n4\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 4, "page_to": 4, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "4a5b6768676e68271ed3e6c5f294fc013da4c85507ddd1bb9acabf74d4bc0d75"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000031", "text": "abstinence from chronic methamphetamine abuse (109). Similarly,\nit has been shown that acute alcohol administration may decrease\nbrain glucose utilization that may persist through early sobriety in\nheavy drinkers (110).\nFinally, in the case of parkinsonian patients, the treatment with\nlevodopa might reduce glucose metabolism regionally and conse-\nquently modify the deﬁned patterns described in these patients.\nTherefore, treatments should be recorded whether the examination\nis conducted in clinically deﬁned “off” or “on” state (47).\nB. Patient Preparation and Precautions\n1. Prearrival.\na. Patient should be fasting for 4–6 h.\nb. Oral hydration with water is encouraged.\nc. Avoid caffeine, alcohol, or drugs that may affect cerebral\nglucose metabolism.\nd. Required medications should be taken with water.\ne. Intravenous ﬂuid containing dextrose or parenteral feeding\nshould be withheld for 4–6 h.\nf. Pregnancy is a relative contraindication especially during\nthe ﬁrst trimester.\ng. Refrain from breast feeding for hours per the Nuclear Regu-\nlatory Commission ACMUI guidance in the United States,\nalthough in many European countries, 24 h is recommended\n(2,111).", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 5, "page_to": 5, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9f9e1a83b5b283dd35c13ffdb698602fac206e2686bb139bf75f5976123c5921"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000032", "text": "g. Refrain from breast feeding for hours per the Nuclear Regu-\nlatory Commission ACMUI guidance in the United States,\nalthough in many European countries, 24 h is recommended\n(2,111).\nSee the Society of Nuclear Medicine procedure Guidelines for\ngeneral imaging.\n2. Preinjection.\na. Environment\nThe environment should be stable before FDG injection\nand during the subsequent uptake phase.\n(1) The patient should be placed in a quiet, dimly lit\nroom.\n(2) Minor background noise is acceptable, and patients\nshould be awake with eyes open. Closing the eyes\ncould decrease metabolism in the occipital cortex, a\ncortical region that might be relevant for speciﬁc\nclinical conditions (as in DLB, characterized by\nhypometabolism of the occipital cortex) (112). In\nany case, a consistent procedure is required in each\ncenter to maintain comparability between examina-\ntions (eyes open/closed), also with respect to the\nnormal control database if semiquantitative analy-\nses based on voxels or regions/volumes of interest\nis performed.\n(3) The patient should be seated or reclined comfortably.\n(5) Place intravenous access at least 10 min before\ninjection to permit accommodation.", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 5, "page_to": 5, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "c03694445032ee3bbbf41cd79960fefb5ee8e92dc3b1a129d8e7222a1813ece1"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000033", "text": "is performed.\n(3) The patient should be seated or reclined comfortably.\n(5) Place intravenous access at least 10 min before\ninjection to permit accommodation.\n(6) Instruct the patient to relax, not to speak or read\nand to avoid major movements.\n(7) Minimize interaction with the patient during at least\n30 min after injection.\nb. Blood Glucose Levels\nBlood glucose levels should be checked before [18F]FDG\nadministration. Hyperglycemia (.110 mg/dL) gradually\nreduces brain [18F]FDG uptake due to the increased com-\npetition of this radiotracer with endogenous glucose for\ntransport by glucose transporters and for phosphorylation\nby hexokinase (113,114). As a general rule, there is a\ndecrease in [18F]FDG inﬂux rate constant (K1) quantitatively\nparalleling blood glucose concentrations, resulting in dete-\nrioration of image quality with increasing glucose concen-\ntrations. Decreased contrast between white-matter and\ngray-matter uptake can be found, which might, at least in\ntheory, impact diagnostic accuracy (115,116), but the exact\nrelationship between the degree of hyperglycemia and\ndiagnostic accuracy of [18F]FDG PET has not been\naddressed systematically. In recent years, some reports", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 5, "page_to": 5, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "937d835aea5902fba98cc7b0e79a2e183cd41c0cf7244cd99def27375cd9d144"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000034", "text": "relationship between the degree of hyperglycemia and\ndiagnostic accuracy of [18F]FDG PET has not been\naddressed systematically. In recent years, some reports\nhave suggested that hyperglycemia might enhance hypo-\nmetabolism\nin\nthe\nposterior\nparieto-occipital\ncortex\n(113,117). These regions encompass the typical AD hypo-\nmetabolic pattern. Therefore, concerns have been raised\nabout the impact of hyperglycemia on the accuracy of PET\nin patients with suspected AD (118). Very few studies\ndirectly addressed this issue, however, and, to date, a mea-\nsurable effect on scan interpretation has not been proven\n(113,119). In any case, an examination should be post-\nponed until an acceptable euglycemic state is reached.\nNotably, acute correction of hyperglycemia with insulin\nusually does not substantially improve brain image quality,\nprobably because the normalization of an increased intracel-\nlular glucose level lags behind the normalization of the\nplasma glucose level (120). Quantitation of regional cerebral\nglucose metabolism with [18F]FDG PET also requires\nsteady-state situations which are not maintained during falling\nplasma glucose levels after administration of insulin. Best", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 5, "page_to": 5, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b7b0d776431c3d40dc78b4ceadd5c4f2b1b43be8ba297d35a111c93df9ae9b26"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000035", "text": "glucose metabolism with [18F]FDG PET also requires\nsteady-state situations which are not maintained during falling\nplasma glucose levels after administration of insulin. Best\nresults for clinical brain [18F]FDG PET imaging in diabetics\ncan be obtained in an euglycemic condition during correct\ntherapeutic management (115,120,121), but diagnostically\nacceptable [18F]FDG PET can be obtained at a plasma glu-\ncose level of 160–180mg/dL. The use of other molecular\nimaging modalities can be considered in patients with uncon-\ntrolled diabetes (i.e., amyloid PET imaging in the suspect of\nAD or perfusion SPECT when appropriate for other clinical\nscenarios) (118,119).\nInterestingly, it has been suggested that hyperglycemia\nobtained by intravenous infusion of 10% glucose solution\ncould enhance detectability in patients with brain tumors\n(112). Procedural guidelines for PET imaging in glioma\nshould be considered for further details (98).\nc. Urinary Bladder\nBefore the scanning procedure, patients should void their\nurinary bladder for maximum comfort during the study\nand to reduce radiation exposure. Advising the patient to\ndrink water and void the bladder again after the scanning", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 5, "page_to": 5, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9ea6a420a0a7e22120c460a953943e43565991a8af0ebf54dc1a0a364636b704"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000036", "text": "urinary bladder for maximum comfort during the study\nand to reduce radiation exposure. Advising the patient to\ndrink water and void the bladder again after the scanning\nsession is also recommended to minimize radiation exposure.\nd. Epilepy Evaluation\nFor presurgical evaluation of epilepsy (70), close monitor-\ning of the patient is required. Such monitoring should start\nbefore injection, as soon as the patient arrives in the\ndepartment, in order to ensure that [18F]FDG is not\nadministered in an ictal/postictal stage. MR images\nacquired in combination with PET or before it, as well as\na well-documented history of seizures before imaging are\nof critical importance for adequate image interpretation.\n3. Precautions and Conscious Sedation.\na. Supervision\nContinuous supervision of patients during the whole scan-\nning procedure is required. This is particularly important\nfor patients with epilepsy and cognitive impairment.\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n5", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 5, "page_to": 5, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "54c6d08376d394a304fba4227675c4f7b5d18d320b0e1d91bbe25e1b5cf3849e"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000037", "text": "b. Sedation\nIn patients with limited ability to cooperate (e.g., due to\ntheir cognitive/behavioral disorders) and in whom no con-\ntraindications against medical sedation exist, it may be\nuseful to apply conscious sedation (e.g., by a short acting\nbenzodiazepine such as intravenous midazolam). Admin-\nistration should take place at least 30 to 40 min after tracer\ninjection, preferably starting only a few minutes before\ndata acquisition. Sedation should be used with caution and\nrather be avoided if dynamic acquisitions are performed\nfor quantiﬁcation of rCMRglc, because of effects of the\nsedative on glucose metabolism and thus also on brain\nuptake of [18F]FDG. Appropriate monitoring (pulse-oxim-\netry) should be performed to prevent cardiopulmonary\ndepression, and appropriate antidote/emergency backup\nshould be foreseen. The dose of sedation should be\nreduced in elderly patients. National regulations in terms\nof the inﬂuence of medical sedation on ﬁtness to drive\nneed to be considered.\nC. Radiopharmaceuticals: [18F]FDG\nSee the SNMMI and EANM Procedure Guideline for Use of\nRadiopharmaceuticals\n1. Recommended Activity for Adults. Previous guidelines men-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7422850ba4fcb1f37e85066a0906a08692ed82d0d7eb4bbe623a1e98def01d34"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000038", "text": "need to be considered.\nC. Radiopharmaceuticals: [18F]FDG\nSee the SNMMI and EANM Procedure Guideline for Use of\nRadiopharmaceuticals\n1. Recommended Activity for Adults. Previous guidelines men-\ntioned 125–740 MBq (typically 150 MBq) when scans are per-\nformed in 3D-mode (122). However, it is important to note that\nscanner sensitivities vary across systems, and the duration of\nimage acquisition also affects the image quality and the dose\nneeded to achieve optimal image quality. For high sensitivity digi-\ntal systems (TOF , 400ps) or large axial ﬁeld of view (also called\ntotal body) systems, activity might be lowered, probably by a fac-\ntor of 2 or more, but limited data are at present available to give\nclear recommendations.\n2. Recommended Activity for Children. Activity administered\nin MBq 5 14 3 multiple (dosage card). Administered activities to\nchildren may also be lower in case of high sensitivity digital sys-\ntems or total-body PET systems, but should not exceed those\nrecommended in the EANM dosage card v.01.02.2014 (123).\nFor the USA, the previous guidelines for children mentioned\n1.85 to 3.7 MBq/kg, with a minimum of 14 MBq and a maximum\nof 148 MBq (124).", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a9b1b5c11e0d8236a3b51048b4ea012ffec103f365f33779855aaa065912bda6"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000039", "text": "recommended in the EANM dosage card v.01.02.2014 (123).\nFor the USA, the previous guidelines for children mentioned\n1.85 to 3.7 MBq/kg, with a minimum of 14 MBq and a maximum\nof 148 MBq (124).\nD. Protocol/Image Acquisition\n1. Instrumentation. PET/CT and PET/MR systems that acquire\nimages in list-mode and in 3D are preferred. In addition, new\nPET/CT and PET/MR systems show increased sensitivity because\nof increased axial ﬁeld of views, silicon photomultipliers (“digital\nPET”) or use of time-of-ﬂight technology (125–130). These prop-\nerties can be beneﬁcial in those cases where the injected radioac-\ntivity or the acquisition time need to be reduced (e.g., pediatric\ncases or patients with limited ability to cooperate). More recently,\ndedicated brain PET scanners have been also proposed to reduce\ncosts and installation constraints on full-time cerebral imaging\nactivities, and large axial ﬁeld of view (LAFOV) PET/CT scanners\noffer the possibility of whole-body dynamic imaging, which\nimproves compartment modeling.\n2. Positioning of the Patient. Careful positioning of the patient’s\nhead is critical, especially for cameras with limited axial ﬁeld of", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "620ee8051e37a5e8e45e08cbac1be099d50af55ecb7dfefeb30bffdbf71d7a2e"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000040", "text": "improves compartment modeling.\n2. Positioning of the Patient. Careful positioning of the patient’s\nhead is critical, especially for cameras with limited axial ﬁeld of\nview. The orbitomeatal line is often used for standardized posi-\ntioning, and the patient\u0001s head can be ﬁxed in place. To prevent\nmovement artifacts, the patient should be instructed to avoid any\nmovements of the head.\n3. Type of Acquisition. Depending on the clinical question and\ntype of equipment, [18F]FDG PET imaging may include:\na. Static Acquisition\nA single set of tomographic images is obtained after brain\nuptake. The static image should usually start at a ﬁxed\npostinjection time, generally 30 to 40 min after injection\nfor evaluating neuronal activity for the diagnosis of neuro-\nlogic diseases, and 60 min after injection or delayed (dual-\ntime-point) scanning can be also considered for neuroon-\ncological\ndiagnostic\npurposes\n(92,98).\nPreferably,\na\ndynamic reconstruction in several frames (1-to-5-min\nframes depending on the total scan time) should be per-\nformed to check potential movement artifacts in addition\nto the static reconstruction. Images should be evaluated by", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "063a490d786560c90610ced874d0e1300366ed780b1567064ce5ce5a4c6f1e77"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000041", "text": "frames depending on the total scan time) should be per-\nformed to check potential movement artifacts in addition\nto the static reconstruction. Images should be evaluated by\nmeans of visual assessment, complemented by semiquan-\ntitative or voxel-based analysis.\nb. Dynamic Acquisition\nMultiple sequential sets of tomographic images are acquired\nfrom the time of administration of [18F]FDG and up to 60min\nafter tinjection. This acquisition is especially used in clinical\nsettings to correct patient’s movements when absolute quantiﬁ-\ncation of rCMRglc is required generally for research purposes\n(see paragraph on absolute quantiﬁcation in G.2.) and perform\nparametric analysis or functional activation studies.\n4. Attenuation Correction. This correction is mandatory for\n[18F]FDG PET brain imaging and is currently performed using CT- or\nMR-based attenuation correction or using mathematically estimated\nattenuation maps. Possible motion artifacts between PET and CT\nacquisitions have to be systematically checked.\na. CT-Based Attenuation Correction\nPET/CT systems can use the CT scan for attenuation cor-\nrection and anatomic correlation. The advantage of a CT", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "79729db3ef37294aad9df9d48ff0bd0c056873486c1789a4bc69161adccc71dd"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000042", "text": "acquisitions have to be systematically checked.\na. CT-Based Attenuation Correction\nPET/CT systems can use the CT scan for attenuation cor-\nrection and anatomic correlation. The advantage of a CT\nscan is that x-rays detection is not impacted by emission\nphotons. Consequently, a CT scan can be performed after\nthe radiopharmaceutical injection. A CT scan can be\ndone for diagnostic purposes, using regular tube current,\nor just for attenuation correction (i.e., a low-dose CT)\nwith low tube current (typically 10–30 mAs). The latter\nhas the advantage to signiﬁcantly reduce the CT-related\nradiation exposure well below 0.5 mSv for most sys-\ntems. The choice of either type of CT scans depends on\nthe purpose of imaging and the clinical indication. If ana-\ntomic information is already available, a low-dose CT for\nthe purpose of attenuation correction can be considered.\nWhen performing PET/CT, it is recommended to check for\nmovement between CT and the PET acquisitions, to avoid\nartifacts in the attenuation correction.\nb. MR-Based Attenuation Correction (131)\nFor hybrid PET/MR systems, attenuation corrections (AC)\nneed to be derived using either a dedicated MR sequence", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "064075015de86140eb5adccde6a08019e8af794ddbbf3a926ddab61975dbe1b3"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000043", "text": "artifacts in the attenuation correction.\nb. MR-Based Attenuation Correction (131)\nFor hybrid PET/MR systems, attenuation corrections (AC)\nneed to be derived using either a dedicated MR sequence\n(MR-AC) or use of CT templates depending on the sys-\ntem’s available methods. In most of the systems only\nMR-AC or CT templates are commercially available now,\nbut improved and more advanced methods using special\nimage reconstruction algorithms and artiﬁcial intelligence\n(132–136) are expected to be offered in future software\nupdates. For MR-AC imaging, the body coil or a dedicated\nbrain/head coil may be required. However, the best perform-\ning MR-AC methods work accurately for [18F]FDG brain\nPET imaging (137).\n6\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 6, "page_to": 6, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "24325a0f0d518075fd1eec30f3c3d805d5050ae74a52cac4c1e4ba2c7eac31c3"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000044", "text": "In all cases, it is recommended to visually control the gener-\nated attenuation correction maps for unforeseen artifacts aris-\ning from metal or dental implants, missing air cavities and\nmissing bones, particularly in MR AC (138). The reader\nshould be aware of the possible qualitative and quantitative\nconsequences of these artifacts and take them into consider-\nation when reading or interpreting the PET images. For\nexample, tracer uptake in cortical brain regions may be\nunderestimated by about 20%, whereas uptake in pons or\ncerebellum may show upward bias in case air cavities are\nnot correctly considered by the MR-AC. Use of CT tem-\nplates can overcome these limitations but may also be less\naccurate in case of abnormal bone anatomy, that is, the tem-\nplates assume healthy anatomic bone structures (absence of\ntrauma). The latter can be overcome by separately making\nindividual CT scans and inserting these into the PET/MR\nreconstruction pipeline for attenuation correction purposes.\nAt present, such a procedure is not routinely available and\nformally approved on PET/MR systems. With the recent\nintroduction of advanced MR-AC methods, accurate AC can", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "424d8df56617778222411286a17716677187c2dc69c82e8a7d3cd6f62a9141a3"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000045", "text": "At present, such a procedure is not routinely available and\nformally approved on PET/MR systems. With the recent\nintroduction of advanced MR-AC methods, accurate AC can\nbe achieved for brain PET images on PET/MRI hybrid sys-\ntems (137). However, especially in case of pooling PET data\ncollected on PET/CT and PET/MR systems, caution is\nadvised with regard to the quality of the MR-AC data.\nc. Mathematically Estimated Attenuation Map\nEspecially for the new emerging brain-dedicated PET sys-\ntems which do not acquire attenuation CT data, mathematic\nestimation of attenuation maps might be applied, like the\nChang method which applies a linear attenuation coefﬁcient\n(139) as provided by the manufacturer for clinical use.\n5. Emission Scan Acquisition. As already noted, in case of a\nstatic image acquisition procedure, the acquisition should not start\nearlier than 30 min after injection. Better contrast between gray\nand white matter, as well between tumors and normal brain tissue,\ncan be obtained with a longer time interval between [18F]FDG\nadministration and data acquisition (e.g., 60 min up to several\nhours for tumors). A standardized acquisition protocol with a ﬁxed", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "029c41952e630917e2a651f2ac0aca43c5b22ec2bac686d1250d025e25887992"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000046", "text": "can be obtained with a longer time interval between [18F]FDG\nadministration and data acquisition (e.g., 60 min up to several\nhours for tumors). A standardized acquisition protocol with a ﬁxed\ntime for acquisition start, generally between 30–40min (for neurologic\ndiagnostic purposes) and 60min after injection (for neurooncological\ndiagnostic purposes), is recommended to improve comparability\nbetween examinations of different patients, follow-up scans, or dif-\nferent centers (e.g., as in multicenter trials). Standard protocols on\nmodern hybrid PET/CT or PET/MR system includes list mode acqui-\nsition in 3D mode. The duration of emission image acquisition should\nbe related to the minimum required number of detected events. Typi-\ncally, data are acquired over 10–15min, possibly less depending on\nthe [18F]FDG dose activity administrated. A whole-body PET/CT\nscan is particularly recommended in case of suspected paraneoplas-\ntic syndromes, lymphoma, or autoimmune/inﬂammatory systemic\ndiseases also involving the brain (e.g., neurosarcoidosis). In special\ncircumstances, when moderately agitated patients are examined,\nacquisition times down to 5 min can be used (140).", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e430ae319953c2cc9d7fd2ca15c3fe7657cec168888270051f61897db4e304d4"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000047", "text": "diseases also involving the brain (e.g., neurosarcoidosis). In special\ncircumstances, when moderately agitated patients are examined,\nacquisition times down to 5 min can be used (140).\nIn the case of a dynamic procedure, typically a 40 to 60-min 3D\ndynamic scan depending on the indication is acquired in list-mode\nshortly before (10 s) or simultaneously with the administration of\n[18F]FDG. During the PET acquisition, it is required to monitor\nhead movement and to correct for any displacements. Use of a\ndedicated head holder or immobilization device to avoid or limit\nhead movements is recommended. When available, a motion\ntracking system may be used to detect motion to retrospectively\ncorrect for any head displacements. It is beyond these guidelines\nto recommend motion correction methods as these are not widely\navailable or generally accepted. Yet, the reader should be aware\nthat it is important to avoid or correct for patient motion in case of\nlong dynamic PET brain studies. After completion of the dynamic\nscan, the list-mode data can be binned (and reconstructed) into for\nexample, 20 to 30 successive time frames to capture kinetics in brain", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "fc536e687203a5be7b85f14e8dae59c4fe98466dd4eba747c469e7f4a740892b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000048", "text": "scan, the list-mode data can be binned (and reconstructed) into for\nexample, 20 to 30 successive time frames to capture kinetics in brain\ntissue over time. Typically, time frames are short (\u00035 to 30 s) on\nthe ﬁrst 5 min of the scan in which the tracer distribution changes\nrapidly over time, progressively increasing to about 300 s time\nframes at later uptake times.\n6. Interventions. Usually, interventions are not necessary to\nanswer routine clinical questions; they are mostly used in research.\nIn the localization of eloquent cortical areas before surgery, stimu-\nlation paradigms like language or motor tasks can be performed.\nCurrently, such activation imaging is mostly performed with func-\ntional MRI (fMRI). If performed with [18F]FDG PET to image spe-\ncial clinical states, especially for MRI contraindications (141–144),\nthese paradigms usually start at the time of injection and have to\nbe maintained for a time period of at least 30 min (145,146).\nImprovement of temporal resolution of PET imaging has also\nbeen proposed using continuous infusion of FDG for intervention\nstudies (147).\nE. Image Processing\nPreferably, images are reconstructed using (ordered subset) itera-", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "575d1ea68e8bb6c528dad15b4305d84021297f5f87049ea308428b75c769f1aa"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000049", "text": "been proposed using continuous infusion of FDG for intervention\nstudies (147).\nE. Image Processing\nPreferably, images are reconstructed using (ordered subset) itera-\ntive reconstruction including use of time of ﬂight (TOF) information,\nwhen available. Current PET scanners allow matrix sizes as high as\n4003 400, but it should be at least 1283 128 pixels. Using a mini-\nmum zoom factor of 2 and the recommended matrix size, the voxel\nsize would be smaller than 2 mm. The number of iterations and sub-\nsets applied should be adapted to the manufacturer recommendations\nbecause it depends on the speciﬁc PET system and TOF perfor-\nmance. Resolution modeling of point spread function (PSF) is also\npart of a new feature in reconstruction software on many available\nPET/CT and PET/MR systems. This resolution modeling may be\napplied to enhance detection of small abnormalities, but it is not yet\nrecommended for either visual or quantitative evaluation due to pro-\nnounced Gibbs artifacts resulting of overestimation of small structure\nuptake with misinterpretation on activity normalization (148,149).\nDifferent initiatives have emerged during the last years in the US as", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "1e3c4be341f479eb66da5fa3511c0b0b726b219dc9c86d1ffb816d08cfdcc8ff"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000050", "text": "uptake with misinterpretation on activity normalization (148,149).\nDifferent initiatives have emerged during the last years in the US as\nan effort to standardize brain PET parameters (for instance, ADNI\nand SCAN ADRC) (150,151). Recently, the EANM Research\nGmbH (EARL) stablished as limits of acceptability an observed\neffective resolution of 5 to 6.5mm FWHM (152,153). Depending on\nthe PET system used, a ﬁnal image resolution of 4–6mm full width at\nhalf maximum (FWHM) typically yields images of adequate resolu-\ntion and noise. If movement artifacts are observed, it can be helpful to\nreconstruct the data in short frames (e.g., 5-min frames) and evaluate\nonly those frames that are not affected by patient motion or spatially\nalign the individual frames before further analysis. It should be noted\nthat nonattenuated series (that should be reconstructed and archived)\ncould be useful in this setting to check for artifacts and for reporting.\nF. Data Display\n\u0001 Color scales typically used for the display of the images are\nspectrum or rainbow scales (154), or gray scales with contin-\nuous progression from low to high uptake.\n\u0001 A standardized image display, also in terms of upper/lower", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "959a4dea8174618333b18b5bf876d1206a895e70f71b489626a4549e29425cba"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000051", "text": "spectrum or rainbow scales (154), or gray scales with contin-\nuous progression from low to high uptake.\n\u0001 A standardized image display, also in terms of upper/lower\ncolor scale thresholding, is advocated to ensure appropriate and\nbest interpretable representation of the reconstructed dataset.\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n7", "section": "These new practice guidelines incorporate advances in PET tech-", "page_from": 7, "page_to": 7, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7af976f74db33be4d85db0f2a2987037b7cf170f9c46975163e0a2f5a42a886d"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000052", "text": "\u0001 Internal landmarks can be used for reorientation to achieve a\nstandardized image display. Current software provided by\nPET manufactures allows an automatic reorientation proce-\ndure based on the intercommissural line. A proper reorientation\non the coronal view is crucial for visual inspection of the scan.\nThis is as the presence of asymmetry between homologous\nstructures in the 2 hemispheres is one of the cornerstones of\nvisual reading. For a more accurate inspection of the medial\ntemporal lobe, a second reorientation can be made along the\nhippocampal axis (the so-called Ohnishi reorientation in which\na patients’ brain is reoriented 30\u0004 upward with respect to the\nbicommissural line on sagittal view (155), for example for tem-\nporal epilepsy or AD.\n\u0001 The display of additional coronal and sagittal images is\nrecommended.\n\u0001 Three-dimensional display of the dataset can be helpful for more\naccurate topographic orientation in some clinical questions.\nG. Quantification\n1. Semiquantitative Procedures. Available tools for automated\nassessment and semiquantiﬁcation, currently provided by PET\nmanufacturers and other vendors, are used in the clinical settings", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a40e0afd7e76c873a951b228b63347cb768ddc0a2d7a7a569527739dd430c0b3"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000053", "text": "1. Semiquantitative Procedures. Available tools for automated\nassessment and semiquantiﬁcation, currently provided by PET\nmanufacturers and other vendors, are used in the clinical settings\nto improve diagnostic performance of readers (15).\nTools for semiquantiﬁcation and voxel-analysis provide individ-\nual statistical maps (parametric or z score maps) aimed to support\nvisual reading and to improve anatomic localization of regions of\nabnormal metabolism. The user should consider that outputs and\nparametric maps generated by this software need to be cross evalu-\nated against the visual evaluation results of the native PET images.\na. Operational Requirement\n\u0001 Normal database for individual comparison\nSemiquantiﬁcation of brain [18F]FDG PET either relying\non a ROI-based or voxelwise statistical evaluation generally\nrequires comparison between an individual patient’s PET\nimage and age-matched databases of PET images obtained\nfrom healthy subjects. Commercial packages incorporate\ntheir own healthy subject database although in some cases,\nonly limited details are available about the composition/\ncharacteristics of this control group. If the software used", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "6715ababd8d8c51c3bc0f0493f5ea66014f306985e5536b963580ccb6edf3aad"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000054", "text": "their own healthy subject database although in some cases,\nonly limited details are available about the composition/\ncharacteristics of this control group. If the software used\ndoes not include an embedded normal controls database,\nthe control group must be built locally in each center. This\nmight be challenging and result in suboptimal control\ngroups also from a clinical point of view (lack of follow-up\nof the controls; simple inclusion of normal scans rather than\nscans of healthy controls; controls recruited among patients\nwho undergo [18F]FDG PET for other indications). Finally,\nin recent years large databases of normal controls have\nbeen publicly shared in the framework of research projects\nand initiatives (156,157). The availability of these databases\nmight contribute to a further spread of the use of semiquan-\ntitative tools also in a clinical setting; however, preparation,\nacquisition and reconstruction parameters should be harmo-\nnized as much as possible with all parameters used to\nacquire the normal subject database to reduce the risk of\ngenerating bias and inconsistencies.\n\u0001 Partial-volume effect correction (PVC)\nGiven the spatial resolution of PET and the size of the", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "c70dd838991825a3e7f148e47c4cc0b881df582dae9739672f1446993185ef21"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000055", "text": "acquire the normal subject database to reduce the risk of\ngenerating bias and inconsistencies.\n\u0001 Partial-volume effect correction (PVC)\nGiven the spatial resolution of PET and the size of the\nbrain structures that need to be inspected, partial-volume\neffect may degrade “quantitative” accuracy of PET images\n(158,159). Because of partial volume/spill-over effect, the\nintensity of a particular voxel not only reﬂects the tracer\nconcentration of that voxel, but also that of the surrounding\narea. However, only some software packages for auto-\nmated analysis of [18F]FDG PET include PVC. The\npartial-volume effect is a potential confounding factor in\nPET imaging studies, mainly in cases of neurodegenerative\ndiseases in which it otherwise is unclear whether any\nobserved decrease in the PET signal is caused by atrophy.\nThis potential confounding effect should be taken into con-\nsideration for the ﬁnal interpretation of the scan, as atrophy\nmay also be the result of other (nonneurodegenerative)\npathophysiologic mechanisms (aging, chronic ischemia,\npostencephalitis brain damage, etc.).\nPVC can at best be applied in case of concomitant or prior", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b312125f01e20f4dd9d860afa964012bf3e5152c56fa8e0ab317bd72eb6bdc0f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000056", "text": "pathophysiologic mechanisms (aging, chronic ischemia,\npostencephalitis brain damage, etc.).\nPVC can at best be applied in case of concomitant or prior\nacquisition of 3D T1-weighted MR scans. However, at\npresent there is no consensus on which PVC method\nshould be used or recommended. Various methods exist\nwith speciﬁc performances. It is also of utmost importance\nthat MR data used during the PET analysis pipeline, either\nfor volume of interest deﬁnitions or PVC are of sufﬁcient\nquality and acquired with 1 3 1x1 mm voxels (or better).\nIt is recommended to correct partial-volume effect by the\nsame MR scan and the same sequence to maintain repro-\nducibility between examinations. Of note, MR-free PVC\ncorrections methods are available and can be considered as\nwell, when MR data are not available or when harmonized\nMR image quality cannot be achieved (152).\n\u0001 Intensity normalization\nIntensity normalization (or scaling) is needed to allow\ncomparing different PET scans or a PET scan against a\nnormal database (160). Accordingly, scaling can be per-\nformed by normalizing to the whole brain (proportional or\nglobal mean scaling), to predeﬁned reference regions", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b2dd509f23ec7a80eeaea15543c39b33bbbb589c05572d4263deb5c65b357c16"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000057", "text": "normal database (160). Accordingly, scaling can be per-\nformed by normalizing to the whole brain (proportional or\nglobal mean scaling), to predeﬁned reference regions\nknown to be spared in speciﬁc clinical settings (i.e., cere-\nbellum, brain stem, pons, primary sensorimotor cortex or\ngray matter) or on a data-driven basis (161–165). The\nnotion of ‘intensity normalization’ is equivalent to SUVR\n(Standardized Uptake Value Ratio) used for other molecu-\nlar brain imaging such as amyloid PET. The underlying\nassumption is that the reference region used is unaffected by\ndisease or method (e.g., MR-AC, point spread function cor-\nrection), which needs to be carefully assessed. Intensity nor-\nmalization is particularly critical when evaluating patients\nwho might show both regions of hypermetabolism and\nhypometabolism such as patients with AE (166). When\nusing software for brain [18F]FDG PET semiquantiﬁcation,\nit is mandatory to consider the count rate normalization\napproach used. In routine clinical practice, it could be help-\nful to use whole brain, pons, and cerebellum for normaliza-\ntion, and to carefully compare each semiquantiﬁcation\noutput with the visual reading result.", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "5136d13906c0d360bd958ff2cf9d945870764dd28717a999f6ef46362b19ffd5"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000058", "text": "ful to use whole brain, pons, and cerebellum for normaliza-\ntion, and to carefully compare each semiquantiﬁcation\noutput with the visual reading result.\nb. Voxel-Based Analytic Approaches\nIn this type of analysis, the minimum unit into which the\nimage is divided is the voxel. Depending on whether the\nvoxel is analyzed as an independent unit (univariate) or\nthe set of voxels and the relationships between them are\nanalyzed these procedures can be classiﬁed as univariate\nor multivariate.\n\u0001 Univariate image analysis\nUnivariate models have the particularity that they ana-\nlyze each voxel or volume of interest (VOI) of the image\nindependently, which allows differences to be established\n8\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "PET manufactures allows an automatic reorientation proce-", "page_from": 8, "page_to": 8, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a20b5b65f15003519369734fdf5133be4862a07a302469766c5aa1f6985a3a7b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000059", "text": "between groups or individuals in terms of metabolic activ-\nity in each voxel.\nDifferent commercial and free-access software are currently\nextensively used to determine abnormalities of regional\n[18F]FDG uptake in an observer independent way and to\nimprove diagnostic accuracy in several clinical settings\n(69,167,168). Here, the following tools are most often used:\n\u0001 3D-SSP (NEUROSTAT) provides a stereotactic sur-\nface projection displays. This tool was speciﬁcally\ndesigned for single-subjects analysis and includes a\ngroup of controls (as well as the possibility to replace\nthis built-in group with a database of local controls).\nIt displays results using different reference regions\nfor normalization (whole brain, pons, thalami, and\ncerebellum) allowing the user to appreciate the effect\nof the different reference regions on the ﬁnal results\n(see above). This algorithm has been used exten-\nsively for research and also implemented on commer-\ncial workstations.\n\u0001 SPM was originally designed for voxel-based group\ncomparisons. However, in more recent years, several\nstudies have validated its use for single-subject analy-\nsis which can be implemented to support visual read-", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b0d058682edea9a7cf2e0d0f623c6749bfeb60c01ac0e239efc02e3f4abdd8f5"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000060", "text": "comparisons. However, in more recent years, several\nstudies have validated its use for single-subject analy-\nsis which can be implemented to support visual read-\ning (65). A dementia-customized [18F]FDG PET\ntemplate has been made available in recent years\nincluding a balanced proportion of [18F]FDG PET\nimages from control subjects and patients (4). The lack\nof a normal control group embedded within the tool is\na potential limitation for its use in a clinical setting\n(see above). Finally, there is still lack of standardiza-\ntion for SPM processing steps even though these steps\ncan introduce bias and, more generally, can affect ﬁnal\nresults (this issue is particularly relevant when choos-\ning a reference region instead of using global count\ndensity for intensity normalization; see above).\n\u0001 Multivariate image analysis\nIt is increasingly recognized that neurodegenerative diseases\nare characterized by stereotyped connectivity changes, and\nthat studying networks provides more insight in pathophysio-\nlogic mechanisms than separate regions. Against univariate\napproaches, multivariable models study all the voxels at\nonce, which allows the relationship between them to be", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "5f483f0d36fdea790a04f430ab516d01881ce58856048e9cef9c7a1b7e2dd91b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000061", "text": "logic mechanisms than separate regions. Against univariate\napproaches, multivariable models study all the voxels at\nonce, which allows the relationship between them to be\nstudied. Those voxels that present a correlation or variance\nof their parallel metabolic activity are considered to belong\nto the same metabolic neural network, so it is assumed that\nthese techniques assess brain metabolic connectivity.\nCovariance analysis techniques are considered appropriate\nmethods to explore interrelated brain regions based on the\nglucose metabolism (neuronal networks) (169). Such an\napproach is the Scaled Subproﬁle Model and Principal\nComponent Analysis (SSM PCA). With this method,\ndisease-related patterns (also referred to as metabolic con-\nnectivity networks) have been identiﬁed in several neurode-\ngenerative diseases (40–42,44,45,47,59,169,170). Disease-\nrelated patterns identiﬁed by SSM PCA not only delineate the\nchanges in neuronal metabolism related to the disease, but\ncan also be used to quantify the degree of pattern expression\nin an individual subject (40–42,44,45,47,59,169,170).\nc. SUV and Ratios\nFor\nbrain\ntumor\nimaging\ntypically\nsemiquantitative", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b050c6a7ce37d7ce58f674e4d8abd7b82edbdcb06b2c042d068ef482993d4ddf"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000062", "text": "can also be used to quantify the degree of pattern expression\nin an individual subject (40–42,44,45,47,59,169,170).\nc. SUV and Ratios\nFor\nbrain\ntumor\nimaging\ntypically\nsemiquantitative\nestimates of glucose metabolism like SUV relative to a\nnormal brain region usually in oncology to the contralat-\neral metabolic uptake (SUVR) are used. For such quantiﬁ-\ncation, standardized acquisition times are required. The\ntotal activity of administered [18F]FDG and the patient’s\nheight and weight for the estimation of body surface are\nalso required. A calibration factor can also be applied as\nwell as for comparative studies between different PET cam-\neras. A static image is sufﬁcient, acquired typically at\n60 min. These semiquantitative estimates can be corrected\nfor blood glucose concentration.\n2. Absolute Quantification. The quantitative assessment of cere-\nbral [18F]FDG/glucose metabolism requires, besides a dynamic emis-\nsion scan, an arterial input function, that is, the measurement of\nplasma [18F]FDG (over time) and glucose concentrations. There is\na need for a calibration factor between scanner events in terms of\ndetected events/voxel/s and in vitro (or online) measurements of", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "fd347d6ae737ba498fb321f755261e3ab4359c668e7bf582d4b85e616dba44d4"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000063", "text": "plasma [18F]FDG (over time) and glucose concentrations. There is\na need for a calibration factor between scanner events in terms of\ndetected events/voxel/s and in vitro (or online) measurements of\nplasma activity concentrations in counts/mL/s (171).\nAlthough dynamic image acquisition from the start of injection\nup to 60 min after injection is considered to be the most accurate\nprocedure, most centers use simpliﬁed protocols based on static\nimages in the clinical setting (172–174).\nAt this respect it is worthy to comment that image-derived input\nfunction from recently developed highly sensitive LAFOV PET/CT\nscanners can avoid the need of invasive blood sampling for kinetic\nmodeling of [18F]FDG (175).\nGlucose metabolism may be derived with either a Patlak plot or a\npharmacokinetic model using the dynamic PET series and the arterial\ninput function. The primary outcome parameter, the net inﬂux rate\nconstant Ki then needs to be multiplied with plasma glucose levels to\nderive the rCMRglc which also take into account the lumped con-\nstant. It is required to measure blood glucose levels during the scan,\nor directly before or after the dynamic PET examination.", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "997b40d218acdd0c7354a78c58367deba4c006006dde0fe5c4c644dd2b4df7ee"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000064", "text": "derive the rCMRglc which also take into account the lumped con-\nstant. It is required to measure blood glucose levels during the scan,\nor directly before or after the dynamic PET examination.\nEstimation of the rCMRglc can be performed by compartmental\nmodeling or using graphical analytic approaches. The quantiﬁca-\ntion can be performed at both region of interest (ROI) or voxel\nlevel. In the ROI-based approach, rCMRglc is estimated in differ-\nent brain regions by ﬁtting the time–activity curve data using the\nmeasured arterial curve as input function. In the voxel-based\napproach, parametric images of rCMRglc can be calculated using\nPatlak analysis, graphical approach, or a basis function approach.\nA correction factor, the so-called “lumped constant” (LC) (176),\ncan be used to convert [18F]FDG “metabolism” values to values\nreﬂecting glucose metabolism (173,177). The lumped constant\nmight vary in pathologic conditions. For instance, in malignant gli-\noma, a higher LC than the one measured in normal brain has been\nreported (178). Under special physiologic conditions, such as pro-\nlonged or extreme fasting, a reduction of glucose metabolism has", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "cd073f5d40c0613311148d52f7c7b407e5520d1daebcfd42304b16972b80984f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000065", "text": "oma, a higher LC than the one measured in normal brain has been\nreported (178). Under special physiologic conditions, such as pro-\nlonged or extreme fasting, a reduction of glucose metabolism has\nbeen observed (179). For instance, in one PET study conducted in\nobese patients before and after 3 wk of fasting, a 50% decrease of\nrCMRglc was reported, with a 25% decrease of the LC (180).\nH. Interpretation\n1. Visual Analysis.\n\u0001 The images should be critically examined during interpre-\ntation for presence of movement or attenuation artifacts.\n\u0001 Variation in color scale, background subtraction or change\nin contrast can be used to facilitate data interpretation.\n\u0001 Data interpretation should take into consideration global\nchanges, such as relative cortical hypometabolism and\nregional decreases or increases in [18F]FDG uptake. Increased\nuptake can be observed in continue active epileptogenic foci,\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n9", "section": "Different commercial and free-access software are currently", "page_from": 9, "page_to": 9, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "85eafd4cc09a19cd6660aead1c344a7855c8d565b83d0fcc93616c53c92118e7"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000066", "text": "tumors, inﬂammation, and pathophysiologically activated\nbrain areas.\n\u0001 Known morphologic changes like cortical sulci and ven-\ntricles enlargement should be considered for the full\ninterpretation of the data. It is helpful to fuse [18F]FDG\nimages with a CT or MRI scan of the individual per-\nformed at the same time (PET/CT, PET/MRI) or inde-\npendently in temporal proximity to the PET scan.\n\u0001 Presence of localized abnormalities with hypometabolism\nor hypermetabolism that can be related to for example,\nneuroinﬂammation, structural damage, atrophy, cerebro-\nvascular lesions, and pathophysiologic circumstances.\n\u0001 Accurate evaluation of brain tumors and identiﬁcation\nof the metabolically most active part of a brain tumor\nbefore biopsy.\n\u0001 Matching of cortical hypometabolism with morphologic\nabnormalities on MRI or with the EEG focus for plan-\nning of epilepsy surgery.\n\u0001 Localization of eloquent cortical areas (e.g., motor,\nvisual, auditive and language) before tumor resection.\nThorough knowledge of the normal physiologic tracer distribu-\ntion and the variants and pitfalls that can occur during image\nacquisition, processing and interpretation is mandatory in order to", "section": "Different commercial and free-access software are currently", "page_from": 10, "page_to": 10, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b192f1b1ccc8f544b5040c1a83e73dfde3383596e9638c4d5845d96b48fc668a"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000067", "text": "Thorough knowledge of the normal physiologic tracer distribu-\ntion and the variants and pitfalls that can occur during image\nacquisition, processing and interpretation is mandatory in order to\nprovide optimal diagnostic information to referring physicians and\npatients (181).\n2. Assisted Visual Analysis. Several studies have investigated\nthe added value of voxel-based analysis (see above) tools in the clini-\ncal setting, and showed higher speciﬁcity compared with visual read-\ning, especially (but not only) for the identiﬁcation of AD-related\npatterns, thereby increasing diagnostic conﬁdence (182–186). On the\nother hand, sensitivity of visual and automatic analyses has been\nshown to be relatively similar although visual analysis obviously is\naffected by the experience of the reader (15). Indeed training and\nexperience in the clinical settings are needed to report brain [18F]FDG\nPET especially given the possibility of subtle defects, as they\nsometimes occur in the early stages of neurodegenerative disease\n(15). Supporting visual analysis with automated observer-independent\napproaches is especially suggested for less-skilled readers and, more", "section": "Different commercial and free-access software are currently", "page_from": 10, "page_to": 10, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "1c36a591259c09b8bbcad71c87d6471621c225de2ee88b79329bbd470e45cb44"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000068", "text": "(15). Supporting visual analysis with automated observer-independent\napproaches is especially suggested for less-skilled readers and, more\nin general, with the aim to reduce interreader variability (187).\nIt is suitable to have a normal database available, preferably\nstudied on the same type of camera, under the same acquisition\ncircumstances (e.g., eyes open/closed) and using the same type of\nreconstruction and attenuation correction. Matching spatial resolu-\ntion is an important parameter needed for optimal database use.\nThis allows assessment of normal variability of regional [18F]FDG\nuptake and improves diagnostic accuracy.\nSemiquantitative/voxel-based approaches to [18F]FDG PET anal-\nysis should always be used in conjunction with visual reading (con-\nsidering visual reading as the ﬁrst step for images evaluation and\nmandatory for quality control). Freeware and commercial software\nare available allowing for semiquantiﬁcation or voxel-based analy-\nsis based on different methods (18,168,188–190).\nVII. DOCUMENTATION AND REPORTING\nA. Goals of a Nuclear Medicine Report\n1. Provide the referring physician with a timely answer to the\nclinical question within the limits of the test", "section": "Different commercial and free-access software are currently", "page_from": 10, "page_to": 10, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7622cad97f17b4b92321c7b95a36b66edc1180dc2e3d6c60c144da9d319b1b8f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000069", "text": "VII. DOCUMENTATION AND REPORTING\nA. Goals of a Nuclear Medicine Report\n1. Provide the referring physician with a timely answer to the\nclinical question within the limits of the test\n2. Document the appropriateness, necessity, and performance\nof the procedure\n3. Expedite and assure correct billing\nB. Direct Communication\nSee also ACR Practice Guideline for Communication: Diagnos-\ntic Radiology\n1. Findings likely to have a signiﬁcant, immediate inﬂuence on\npatient care should be communicated to the requesting phy-\nsician or an appropriate representative in a timely manner.\n2. Actual or attempted communication should be documented\nas appropriate.\n3. Signiﬁcant discrepancies between an initial and ﬁnal report\nshould be promptly reconciled by direct communication.\nC. Written Communication\n1. Include the items in section D., Contents of a Nuclear Medi-\ncine Report, which are appropriate for a particular study.\n2. Many items, such as patient identiﬁcation or radiopharma-\nceutical information, can be transferred to the report auto-\nmatically or entered by a technologist or secretary.\n3. The ﬁnal report should be proofread.\n4. Electronic signature instead of a written signature is accept-", "section": "Different commercial and free-access software are currently", "page_from": 10, "page_to": 10, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2f84b3458ad2a318df69a9e26e14d3cfb5af8a4b055d3586bb289566f2460453"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000070", "text": "matically or entered by a technologist or secretary.\n3. The ﬁnal report should be proofread.\n4. Electronic signature instead of a written signature is accept-\nable if access to the signature mechanism is secure.\n5. Copies of the report should be sent to the requesting physi-\ncian, made available to other identiﬁed health care workers,\nand archived for an appropriate period of time.\nD. Contents of a Nuclear Medicine Report\n1. Study Identification.\na. Patient name\nb. Other information to uniquely identify the patient such as\nsex, date of birth, medical record number, or universal\npatient code\nc. Requesting physician and other appropriate health care\nproviders such as the primary care physician\nd. Type of study\ne. Date of study\nf. Study accession number (in a well-integrated information sys-\ntem, the study accession number may not need to be visible)\ng. Completion dates and times\n2. Clinical Information.\na. Indications for the study\nb. Other relevant history:\n\u0001 Brief history emphasizing the main reason for the study\nfor example, memory loss.\n\u0001 Duration of the problem.\n\u0001 Other essential clinical information including medications.\n\u0001 Recent ﬁndings on prior nuclear medicine studies.", "section": "Different commercial and free-access software are currently", "page_from": 10, "page_to": 10, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "bc569cef1b9599192127ac450054ec31f16ac6cf2ff22e43b14f58e47c36a7c3"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000071", "text": "for example, memory loss.\n\u0001 Duration of the problem.\n\u0001 Other essential clinical information including medications.\n\u0001 Recent ﬁndings on prior nuclear medicine studies.\n\u0001 Findings on other imaging modalities such as MRI\nc. Information needed for billing such as referral number,\npatient status (e.g., inpatient/outpatient), or diagnostic codes\n(e.g., ICD-9-CM code)\n\u0001 Insurance carriers may not accept phrases such as “rule\nout” or “possible.”\n\u0001 List the diagnosis to the highest level of speciﬁcity known\nat the time of billing, or if no diagnosis is known, the per-\ntinent symptom or sign that led to the procedure.\n3. Procedure Description.\na. Radiopharmaceutical (here, [18F]FDG)\nb. Administered dose\nc. Route of administration\nd. Timing\nof\nimaging\nrelative\nto\nradiopharmaceutical\nadministration\n10\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "Different commercial and free-access software are currently", "page_from": 10, "page_to": 10, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "f701bb7ca498be1479ad223a2b7f29d9740dd7c35ed81c85f9f58b94afe53222"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000072", "text": "e. Blood glucose level\nf. Imaging technique (Instrumentation used that is, PET with\nmeasured attenuation correction, PET with transmission cor-\nrection, attenuation correction with CT or MRI, or dedicated\nbrain PET scanner with or without CT attenuation correc-\ntion), including alteration in normal procedure. that is,\nwhether the images were acquired using a PET/CT or\nPET/MR system, and procedure performed, such as arterial\nblood sampling. If CT is acquired for diagnostic purposes,\nalso include a description of the scanning parameters\nincluding dosimetry. In cases of PET/MR, report the type\nof sequences that were acquired during the imaging ses-\nsion (e.g., structural MR, T1-w, T2-w, FLAIR, diffusion\nweighted, arterial spin labeling, resting-state fMRI, etc.).\ng. If sedation is performed, brieﬂy describe the procedure,\nincluding type of medication and time of sedation in rela-\ntion to the radiotracer injection.\nh. In epileptic patients, brieﬂy describe the procedure of\nEEG recording, when performed.\ni. Complications or patient reactions\n4. Description of Findings.\na. Signiﬁcant positive ﬁndings as well as pertinent negative\nﬁndings should be mentioned. Describe whether [18F]FDG", "section": "Different commercial and free-access software are currently", "page_from": 11, "page_to": 11, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "bf01c841eef67579fe18732474cdddf6d6aea55fe5329a1c9cdb835125657785"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000073", "text": "i. Complications or patient reactions\n4. Description of Findings.\na. Signiﬁcant positive ﬁndings as well as pertinent negative\nﬁndings should be mentioned. Describe whether [18F]FDG\nPET ﬁndings are normal or abnormal. If ﬁndings are\nabnormal, describe the location and intensity of abnormal\n[18F]FDG uptake. Functional topography can be used as\nwell as anatomic descriptions.\nb. Image quality or other causes of study limitations, for\nexample, patient motion\nc. A reference range may be useful for quantitative values.\nd. Correlation with other imaging studies should be documen-\nted in the report describing the date and type of the prior\nstudy. If other studies are not available for correlation, this\nshould also be mentioned in the written report. Compara-\ntive data: Comparisons with previous examinations and\nreports, if available, have to be part of the report. Further-\nmore, results of morphologic imaging modalities should\nalso be considered for interpretation. Nondiagnostic CT\nscans only used for attenuation in PET/CT should be used\nwith caution for structural interpretation.\n5. Impression.\na. A separate impression should be included for all but the\nshortest reports.", "section": "Different commercial and free-access software are currently", "page_from": 11, "page_to": 11, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2d87dee31c3fa3f36f4085753db1b4d02dc0116be5c83ee182176b9c11e90ce0"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000074", "text": "scans only used for attenuation in PET/CT should be used\nwith caution for structural interpretation.\n5. Impression.\na. A separate impression should be included for all but the\nshortest reports.\nb. The impression should address the clinical indication for\nthe scan.\nc. If the PET examination presents a generally accepted dis-\nease pattern, this should be said in the conclusion, and if\npossible, using a statement that indicates the most proba-\nble diagnosis considering the pattern only in the context of\nthe clinical presentation and hypothesis. Any (subjective)\ninterpretation not based on such criteria has to be explic-\nitly stated and considered as hypothetical. A differential\ndiagnosis should be given when appropriate.\n6. Comments.\na. Study limitations or source of errors (191):\n\u0001 Unintended cerebral activation (i.e., visual or motor\nactivation)\n\u0001 Artifacts (patient movement during PET acquisition or\nbetween PET and CT/MRI, camera related, induced by\ninappropriate processing) as well as MR-based AC\nbiases (missing bones, air cavities, metal implants etc.)\n\u0001 Psychotropic drugs or corticosteroid use\n\u0001 Sedation\n\u0001 Incomplete intravenous tracer injection", "section": "Different commercial and free-access software are currently", "page_from": 11, "page_to": 11, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "49fc1ce582cd7f222e3d1eaaa178b82649f1feaf418a74a11b10f3a9d1c392cc"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000075", "text": "biases (missing bones, air cavities, metal implants etc.)\n\u0001 Psychotropic drugs or corticosteroid use\n\u0001 Sedation\n\u0001 Incomplete intravenous tracer injection\n\u0001 No or insufﬁcient attenuation correction\n\u0001 Soft tissue or skull uptake after surgery in the area of\nthe skull or brain\n\u0001 Recent radio- or chemotherapy\nb. Recommendations for further procedures, if appropriate\nc. Documentation of direct communication of results includ-\ning the name of the physician or physician designate and\ntime/date of contact\nd. Comments may be included in the Impression section,\nespecially when brief.\nVIII. EQUIPMENT SPECIFICATION\nEquipment speciﬁcation for each procedure is given in the\nrespective procedure guidelines.\nIX. QUALITY CONTROL AND IMPROVEMENT, SAFETY,\nINFECTION CONTROL, AND PATIENT\nEDUCATION CONCERNS\nSee also the SNMMI Guideline for General Imaging and\nEANM Physics Guidelines\nPolicies and procedures related to quality, patient education,\ninfection control, and safety should be developed and implemented\nin accordance with the ACR Policy on Quality Control or national\nequivalence, and Patient Education Concerns appearing elsewhere\nin the ACR Practice Guidelines and Technical Standards book, or", "section": "Different commercial and free-access software are currently", "page_from": 11, "page_to": 11, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "6a1ac74e24c6fd22b55e616f78beddb3847345776024dfd38f4a3f8667cfbcd1"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000076", "text": "in accordance with the ACR Policy on Quality Control or national\nequivalence, and Patient Education Concerns appearing elsewhere\nin the ACR Practice Guidelines and Technical Standards book, or\nnational equivalence.\nPhysician quality control should also be done regularly to assure\nconsistent, accurate physician interpretation of results.\nEquipment performance monitoring should be in accordance\nwith ACR Technical Standards for Medical Nuclear Physics Per-\nformance Monitoring of CT and Nuclear Medicine Equipment, or\nnational equivalence.\nInformation speciﬁc to the procedure should also be included in\neach guideline.\nX. RADIATION SAFETY IN IMAGING\nSee also the SNMMI Guideline for General Imaging, and\nEANM Dosimetry and Radiopharmaceutical Guidelines\nIt is the position of SNMMI and EANM that patient exposure\nto ionizing radiation should be at the minimum level consistent\nwith obtaining a diagnostic examination. Reduction in patient radi-\nation exposure may be accomplished by administering less radio-\npharmaceutical when the technique or equipment used for imaging\ncan support such an action. Each patient procedure is unique\nand the methodology to achieve minimum exposure while main-", "section": "Different commercial and free-access software are currently", "page_from": 11, "page_to": 11, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "77a10cd5e3d3335772df4bec1bee8fcb1a2bfb24e9fc109bd11a3865743f5958"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000077", "text": "pharmaceutical when the technique or equipment used for imaging\ncan support such an action. Each patient procedure is unique\nand the methodology to achieve minimum exposure while main-\ntaining diagnostic accuracy needs to be viewed in this light.\nRadiopharmaceutical dose ranges outlined in this document should\nbe considered as a guide. Dose reduction techniques should be\nused when appropriate. The same principles should be applied\nwhen CT is used in a hybrid imaging procedure. CT acquisition\nprotocols should be optimized to provide the information needed\nwhile minimizing patient radiation exposure. Minimizing radiation\ndose is especially important in children.\nInfants have a greater relative brain mass (10%) than adults\n(2%–3%), so the percentage uptake of injected [18F]FDG is\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n11", "section": "Different commercial and free-access software are currently", "page_from": 11, "page_to": 11, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "8454d74a50badb3982d1274fdeff1a7dce875f06aa068339ce013ddecc55ad69"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000078", "text": "higher. Although in new-born infants, sufﬁcient image quality\nmay be achieved with an injected dose as low as 10 MBq (192)\n(in part also based on lower tissue attenuation), the advocated min-\nimal dose stated from the pediatric dose card for the EANM is fol-\nlowed in these guidelines.\nEstimated radiation doses in adults and children are shown in\nTable 1.\nFor CT, the effective dose depends on collimation and scan\ntype (axial, helical) (193) but is usually lower than 0.3 mSv for a\nso-called low-dose CT and typically around 2 mSv or lower for a\ndiagnostic high-quality CT.\nXI. ACKNOWLEDGMENTS\nThe Committee on Guidelines includes Kevin J. Donohoe, MD\n(Chair) (Beth Israel Deaconess Medical Center, Boston, MA); Sue\nAbreu, MD (Sue Abreu Consulting, Nichols Hills, OK); Helena\nBalon, MD (Beaumont Health System, Royal Oak, MI); Twyla Bar-\ntel, DO (UAMS, Little Rock, AR); Paul E. Christian, CNMT, BS,\nPET (Huntsman Cancer Institute, University of Utah, Salt Lake City,\nUT); Dominique Delbeke, MD (Vanderbilt University Medical Cen-\nter, Nashville, TN); Vasken Dilsizian, MD (University of Maryland\nMedical Center, Baltimore, MD); Kent Friedman, MD (NYU School", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "ea18cb0a6f7435f6e8e9ac102201daa7ab5acb7fa263299ae2cfdee103c2a980"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000079", "text": "UT); Dominique Delbeke, MD (Vanderbilt University Medical Cen-\nter, Nashville, TN); Vasken Dilsizian, MD (University of Maryland\nMedical Center, Baltimore, MD); Kent Friedman, MD (NYU School\nof Medicine, New York, NY); James R. Galt, PhD (Emory University\nHospital, Atlanta, GA); Jay A. Harolds, MD (OUHSC-Department of\nRadiologic Science, Edmond, OK); Aaron Jessop, MD (UT MD\nAnderson Cancer Center, Houston, TX); David H. Lewis, MD (Har-\nborview Medical Center, Seattle, WA); J. Anthony Parker, MD, PhD\n(Beth Israel Deaconess Medical Center, Boston, MA); James A.\nPonto, RPh, BCNP (University of Iowa, Iowa City, IA); Lynne T.\nRoy, CNMT (Cedars/Sinai Medical Center, Los Angeles, CA); Scho-\nder, MD (Memorial Sloan-Kettering Cancer Center, New York, NY);\nBarry L. Shulkin, MD, MBA (St. Jude Children’s Research Hospital,\nMemphis, TN); Michael G. Stabin, PhD (Vanderbilt University,\nNashville, TN); and Mark Tulchinsky, MD (Milton S. Hershey Med\nCenter, Hershey, PA).\nXII. BOARD OF DIRECTORS APPROVAL DATES\nVersion 2.0 of this procedure standard was approved June 7, 2024.\nXIII. REFERENCES\n1. Waxman AD, Herholz K, Lewis DH, et al. Society of Nuclear Medicine proce-", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "077a7ce9b9b8f22de4c5c4088a58684da98f410af52e0344d80e188fa6a3e3c0"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000080", "text": "XII. BOARD OF DIRECTORS APPROVAL DATES\nVersion 2.0 of this procedure standard was approved June 7, 2024.\nXIII. REFERENCES\n1. Waxman AD, Herholz K, Lewis DH, et al. Society of Nuclear Medicine proce-\ndure guideline for FDG PET brain imaging: version 1. SNMMI website. https://\nsnmmi.org/common/Uploaded%20ﬁles/Web/Clinical%20Practice/Procedure%20\nStandards/2009/Society%20of%20Nuclear%20 Medicine%20Procedure%20\nGuideline%20 for%20FDG%20PET%20Brain%20Imaging.pdf. Published February\n8, 2009. Accessed September 18, 2024.\n2. Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain\nPET imaging using. Eur J Nucl Med Mol Imaging. 2022;49:632–651.\n3. Zimmer ER, Parent MJ, Souza DG, et al. [18F]FDG PET signal is driven by astro-\nglial glutamate transport. Nat Neurosci. 2017;20:393–395.\n4. Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine\nand European Academy of Neurology recommendations for the use of brain. Eur\nJ Neurol. 2018;25:1201–1217.\n5. Ossenkoppele R, Schonhaut DR, Sch€oll M, et al. Tau PET patterns mirror clinical\nand neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–1567.", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b25aee02f41fbdb00def2d07287a106f13ee219bb898dee58d9cfa239be2737b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000081", "text": "J Neurol. 2018;25:1201–1217.\n5. Ossenkoppele R, Schonhaut DR, Sch€oll M, et al. Tau PET patterns mirror clinical\nand neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–1567.\n6. Ch\u0001etelat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison\nbetween grey matter hypometabolism and atrophy in Alzheimer’s disease. Brain.\n2008;131:60–71.\n7. Kim EJ, Cho SS, Jeong Y, et al. Glucose metabolism in early onset versus late onset\nAlzheimer’s disease: an SPM analysis of 120 patients. Brain. 2005;128:1790–1801.\n8. Minoshima S, Cross D, Thientunyakit T, Foster NL, Drzezga AF-FDG. PET\nimaging in neurodegenerative dementing disorders: insights into subtype classiﬁ-\ncation, emerging disease categories, and mixed dementia with copathologies.\nJ Nucl Med. 2022;63(suppl 1):2S–12S.\n9. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a\nbiological deﬁnition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562.\n10. Tan MS, Ji X, Li JQ, et al. Longitudinal trajectories of Alzheimer’s ATN bio-\nmarkers in elderly persons without dementia. Alzheimers Res Ther. 2020;12:55.", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7ba498fc13c673402819019716a6df43787cb0de0c5cf1c1b36ef738c8c5453d"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000082", "text": "10. Tan MS, Ji X, Li JQ, et al. Longitudinal trajectories of Alzheimer’s ATN bio-\nmarkers in elderly persons without dementia. Alzheimers Res Ther. 2020;12:55.\n11. Ou YN, Xu W, Li JQ, et al. FDG-PET as an independent biomarker for Alzhei-\nmer’s biological diagnosis: a longitudinal study. Alzheimers Res Ther. 2019;11:57.\n12. Caroli A, Prestia A, Galluzzi S, et al. Mild cognitive impairment with suspected non-\namyloid pathology (SNAP): prediction of progression. Neurology. 2015;84:508–515.\n13. Iaccarino L, Sala A, Perani D. Initiative AsDN. Predicting long-term clinical stability in\namyloid-positive subjects by FDG-PET. Ann Clin Transl Neurol. 2019;6:1113–1120.\n14. Ch\u0001etelat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the\ndiagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol.\n2020;19:951–962.\n15. Nobili F, Festari C, Altomare D, et al. Automated assessment of FDG-PET for\ndifferential diagnosis in patients with neurodegenerative disorders. Eur J Nucl\nMed Mol Imaging. 2018;45:1557–1566.\n16. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of\ndementia with Lewy bodies: fourth consensus report of the DLB consortium. Neu-", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9db5282e41073665c7056ed694584b97751b8d2bd91c022efdcb6350e9ee19df"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000083", "text": "Med Mol Imaging. 2018;45:1557–1566.\n16. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of\ndementia with Lewy bodies: fourth consensus report of the DLB consortium. Neu-\nrology. 2017;89:88–100.\n17. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic cri-\nteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:\n2456–2477.\n18. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer demen-\ntia and controls by automated analysis of multicenter FDG PET. Neuroimage.\n2002;17:302–316.\n19. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET\ndiagnosis of mild cognitive impairment, Alzheimer’s disease, and other demen-\ntias. J Nucl Med. 2008;49:390–398.\n20. Garibotto V, Herholz K, Boccardi M, et al. Clinical validity of brain ﬂuorodeoxy-\nglucose positron emission tomography as a biomarker for Alzheimer’s disease in\nthe context of a structured 5-phase development framework. Neurobiol Aging.\n2017;52:183–195.\nTABLE 1\nRadiation Dosimetry in Adults and Children\nParameter\nAdults\nChildren\nRadiopharmaceutical\n[18F]FDG\n[18F]FDG\nAdministered activity*\n150–370 MBq (5–10 mCi)", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "0bbef6730287bef5f984147ab26bf39088137e48b76cc2db9ad524c6c5680676"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000084", "text": "2017;52:183–195.\nTABLE 1\nRadiation Dosimetry in Adults and Children\nParameter\nAdults\nChildren\nRadiopharmaceutical\n[18F]FDG\n[18F]FDG\nAdministered activity*\n150–370 MBq (5–10 mCi)\nNorth America: 3.7 MBq/kg (0.1 mCi/kg)\nEurope: 5.18–7.4 MBq/kg (0.14–0.20 mCi/kg)\nOrgan receiving the largest radiation\ndose† (mGy/MBq)\nUrinary bladder, 0.13\nUrinary bladder, 0.34\nEffective dose† (mSv/MBq)\n0.019\n0.056\n*Depends on equipment limitations, speciﬁc application, and patient compliance.\n†Calculations based on Table C31 in ICRP 128.\n12\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "Different commercial and free-access software are currently", "page_from": 12, "page_to": 12, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "0676f0f2c7bb3da4c5f28ea2ba5550a29c7904b2d0938658f12b68c6e3645813"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000085", "text": "21. Ch\u0001etelat G, Arbizu J, Barthel H, et al. Finding our way through the labyrinth of\ndementia biomarkers. Eur J Nucl Med Mol Imaging. 2021;48:2320–2324.\n22. Singh TD, Josephs KA, Machulda MM, et al. Clinical, FDG and amyloid PET\nimaging in posterior cortical atrophy. J Neurol. 2015;262:1483–1492.\n23. Whitwell JL, Graff-Radford J, Singh TD, et al. F-FDG PET in posterior cortical\natrophy and dementia with lewy bodies. J Nucl Med. 2017;58:632–638.\n24. Migliaccio R, Agosta F, Basaia S, et al. Functional brain connectome in posterior\ncortical atrophy. Neuroimage Clin. 2020;25:102100.\n25. Bouwman F, Orini S, Gandolfo F, et al. Diagnostic utility of FDG-PET in the dif-\nferential diagnosis between different forms of primary progressive aphasia. Eur J\nNucl Med Mol Imaging. 2018;45:1526–1533.\n26. Salat DH, Robinson ME, Miller DR, Clark DC, McGlinchey RE. Neuroimaging\nof deployment-associated traumatic brain injury (TBI) with a focus on mild TBI\n(mTBI) since 2009. Brain Inj. 2017;31:1204–1219.\n27. Townley RA, Botha H, Graff-Radford J, et al. F-FDG PET-CT pattern in idio-\npathic normal pressure hydrocephalus. Neuroimage Clin. 2018;18:897–902.", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "ee3cf54d246f1b48046ebf3874df7dc3e79dcb6889ecbe9f0908dae395d3d55d"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000086", "text": "(mTBI) since 2009. Brain Inj. 2017;31:1204–1219.\n27. Townley RA, Botha H, Graff-Radford J, et al. F-FDG PET-CT pattern in idio-\npathic normal pressure hydrocephalus. Neuroimage Clin. 2018;18:897–902.\n28. Watanabe Y. PET/SPECT/MRI/fMRI Studies in the myalgic encephalomyelitis/\nchronic fatigue syndrome. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde\nA, Sommer IE, eds. PET and SPECT in Psychiatry. Springer International Pub-\nlishing; 2021:985–1001.\n29. Meyer PT, Hellwig S, Blazhenets G, Hosp JA. Molecular imaging ﬁndings on\nacute and long-term effects of COVID-19 on the brain: a systematic review.\nJ Nucl Med. 2022;63:971–980.\n30. Guedj E, Campion JY, Dudouet P, et al. F-FDG brain PET hypometabolism\nin patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48:2823–\n2833.\n31. Verger A, Barthel H, Tolboom N, et al. 2-[18F]-FDG PET for imaging brain\ninvolvement in patients with long COVID: perspective of the EANM neuroimag-\ning committee. Eur J Nucl Med Mol Imaging. 2022;49:3599–3606.\n32. Videbech P. PET measurements of brain glucose metabolism and blood ﬂow\nin major depressive disorder: a critical review. Acta Psychiatr Scand. 2000;\n101:11–20.", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "457a1e9ca37adfa8011d4cdca3b3f1beab753a37a308424489b9ea6fd998762b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000087", "text": "32. Videbech P. PET measurements of brain glucose metabolism and blood ﬂow\nin major depressive disorder: a critical review. Acta Psychiatr Scand. 2000;\n101:11–20.\n33. Kimbrell TA, Ketter TA, George MS, et al. Regional cerebral glucose utilization\nin patients with a range of severities of unipolar depression. Biol Psychiatry.\n2002;51:237–252.\n34. Kennedy SH, Evans KR, Kr€uger S, et al. Changes in regional brain glucose\nmetabolism measured with positron emission tomography after paroxetine treat-\nment of major depression. Am J Psychiatry. 2001;158:899–905.\n35. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in\nevaluation of dementia: regional brain metabolism and long-term outcome.\nJAMA. 2001;286:2120–2127.\n36. Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. Single photon emission\ncomputed tomography/positron emission tomography molecular imaging for par-\nkinsonism: a fast-developing ﬁeld. Ann Neurol. 2021;90:711–719.\n37. Meyer PT, Frings L, R€ucker G, Hellwig S. 18F-FGD PET in Parkinsonism: differential\ndiagnosis and evaluation of cognitive impairment. J Nucl Med. 2017;58:1888–1898.", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e35a2485aabba4d797ab93c95382889e3de296ccedefd63267b97535e0ef07c8"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000088", "text": "37. Meyer PT, Frings L, R€ucker G, Hellwig S. 18F-FGD PET in Parkinsonism: differential\ndiagnosis and evaluation of cognitive impairment. J Nucl Med. 2017;58:1888–1898.\n38. Walker Z, Gandolfo F, Orini S, et al. Clinical utility of FDG PET in Parkinson’s\ndisease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol\nImaging. 2018;45:1534–1545.\n39. Whitwell JL, H€oglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis\nin PSP: where are we and where do we need to be? Mov Disord. 2017;32:955–971.\n40. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurol-\nogy: concepts and applications. Ann Neurol. 2012;72:635–647.\n41. Ge J, Wu J, Peng S, et al. Reproducible network and regional topographies of\nabnormal glucose metabolism associated with progressive supranuclear palsy:\nmultivariate and univariate analyses in American and Chinese patient cohorts.\nHum Brain Mapp. 2018;39:2842–2858.\n42. Niethammer M, Tang CC, Feigin A, et al. A disease-speciﬁc metabolic brain net-\nwork associated with corticobasal degeneration. Brain. 2014;137:3036–3046.\n43. Mart\u0001ı-Andr\u0001es G, van Bommel L, Meles SK, et al. Multicenter validation of meta-", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "9ad2d5e9db564fa81b325581bdcd8d0f5d24d4b750fc69628efa54239e2bd9b8"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000089", "text": "work associated with corticobasal degeneration. Brain. 2014;137:3036–3046.\n43. Mart\u0001ı-Andr\u0001es G, van Bommel L, Meles SK, et al. Multicenter validation of meta-\nbolic abnormalities related to PSP according to the MDS-PSP criteria. Mov Dis-\nord. 2020;35:2009–2018.\n44. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of\nparkinsonian disorders. Neuroimage. 2005;26:912–921.\n45. Eckert T, Tang C, Ma Y, et al. Abnormal metabolic networks in atypical parkin-\nsonism. Mov Disord. 2008;23:727–733.\n46. Meles SK, Renken RJ, Pagani M, et al. Abnormal pattern of brain glucose metab-\nolism in Parkinson’s disease: replication in three European cohorts. Eur J Nucl\nMed Mol Imaging. 2020;47:437–450.\n47. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkin-\nson’s disease. Brain. 2006;129:2667–2678.\n48. Meles SK, Renken RJ, Janzen A, et al. The Metabolic pattern of idiopathic REM\nsleep behavior disorder reﬂects early-stage Parkinson disease. J Nucl Med. 2018;\n59:1437–1444.\n49. Orso B, Mattioli P, Yoon EJ, et al. Validation of the REM behaviour disorder\nphenoconversion-related pattern in an independent cohort. Neurol Sci. 2023;44:\n3161–3168.", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2e81806fa9aae45cc3b4f650c841b20c557bb97e74613425fcdefed72fb88f2f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000090", "text": "59:1437–1444.\n49. Orso B, Mattioli P, Yoon EJ, et al. Validation of the REM behaviour disorder\nphenoconversion-related pattern in an independent cohort. Neurol Sci. 2023;44:\n3161–3168.\n50. Zhao P, Zhang B, Gao S, Li X. Clinical features, MRI, and 18F-FDG-PET in dif-\nferential diagnosis of Parkinson disease from multiple system atrophy. Brain\nBehav. 2020;10:e01827.\n51. H€oglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supra-\nnuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–864.\n52. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, H€oglinger GU. Advances in pro-\ngressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic\napproaches. Lancet Neurol. 2017;16:552–563.\n53. Agosta F, Altomare D, Festari C, et al. Clinical utility of FDG-PET in amyotro-\nphic lateral sclerosis and Huntington’s disease. Eur J Nucl Med Mol Imaging.\n2018;45:1546–1556.\n54. van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet.\n2017;390:2084–2098.\n55. Pagani M, €Oberg J, De Carli F, et al. Metabolic spatial connectivity in amyotro-\nphic lateral sclerosis as revealed by independent component analysis. Hum Brain", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "e1f9086262a8d8d3b42f670be17a7f7382b9b6b9be9dc1a18aecd200226d350a"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000091", "text": "2017;390:2084–2098.\n55. Pagani M, €Oberg J, De Carli F, et al. Metabolic spatial connectivity in amyotro-\nphic lateral sclerosis as revealed by independent component analysis. Hum Brain\nMapp. 2016;37:942–953.\n56. Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere\nK. Prospective validation of 18F-FDG brain PET discriminant analysis methods in\nthe diagnosis of amyotrophic lateral sclerosis. J Nucl Med. 2016;57:1238–1243.\n57. Van Laere K, Vanhee A, Verschueren J, et al. Value of 18ﬂuorodeoxyglucose-\npositron-emission tomography in amyotrophic lateral sclerosis: a prospective\nstudy. JAMA Neurol. 2014;71:553–561.\n58. Van Weehaeghe D, Devrome M, Schramm G, et al. Combined brain and spinal\nFDG PET allows differentiation between ALS and ALS mimics. Eur J Nucl Med\nMol Imaging. 2020;47:2681–2690.\n59. Tang CC, Feigin A, Ma Y, et al. Metabolic network as a progression biomarker\nof premanifest Huntington’s disease. J Clin Invest. 2013;123:4076–4088.\n60. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in pre-\nclinical Huntington’s disease. Brain. 2007;130:2858–2867.\n61. Herben-Dekker M, van Oostrom JC, Roos RA, et al. Striatal metabolism and psy-", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "8015232dffbdd347e77abc58350a1f851c4c55986a1be6fd3f8a712eb06d8668"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000092", "text": "clinical Huntington’s disease. Brain. 2007;130:2858–2867.\n61. Herben-Dekker M, van Oostrom JC, Roos RA, et al. Striatal metabolism and psy-\nchomotor speed as predictors of motor onset in Huntington’s disease. J Neurol.\n2014;261:1387–1397.\n62. Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F.\n18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-\nonset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;\n39:1030–1036.\n63. Hellem MNN, Vinther-Jensen T, Anderberg L, et al. Hybrid 2-[18F] FDG\nPET/MRI in premanifest Huntington’s disease gene-expansion carriers: the signif-\nicance of partial volume correction. PLoS One. 2021;16:e0252683.\n64. Peralta C, Biafore F, Depetris TS, Bastianello M. Recent advancement and clini-\ncal implications of 18FDG-PET in Parkinson’s disease, atypical parkinsonisms,\nand other movement disorders. Curr Neurol Neurosci Rep. 2019;19:56.\n65. Verger A, Lagarde S, Maillard L, Bartolomei F, Guedj E. Brain molecular imag-\ning in pharmacoresistant focal epilepsy: current practice and perspectives. Rev\nNeurol (Paris). 2018;174:16–27.", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "68aa9d37ae4ea0e23449170efbf259aaa4fd79ccaf708e90a7869f6d7f2648c3"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000093", "text": "65. Verger A, Lagarde S, Maillard L, Bartolomei F, Guedj E. Brain molecular imag-\ning in pharmacoresistant focal epilepsy: current practice and perspectives. Rev\nNeurol (Paris). 2018;174:16–27.\n66. Guedj E, Bonini F, Gavaret M, et al. 18FDG-PET in different subtypes of tem-\nporal lobe epilepsy: SEEG validation and predictive value. Epilepsia. 2015;\n56:414–421.\n67. Lagarde S, Boucekine M, McGonigal A, et al. Relationship between PET metabo-\nlism and SEEG epileptogenicity in focal lesional epilepsy. Eur J Nucl Med Mol\nImaging. 2020;47:3130–3142.\n68. Henry TR, Votaw JR. The role of positron emission tomography with [18F]ﬂuoro-\ndeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am. 2004;\n14:517–535.\n69. Van Paesschen W, Dupont P, Sunaert S, Gofﬁn K, Van Laere K. The use of\nSPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol. 2007;\n20:194–202.\n70. Traub-Weidinger T, Arbizu J, Barthel H, et al. EANM practice guidelines for an\nappropriate use of PET and SPECT for patients with epilepsy. Eur J Nucl Med\nMol Imaging. 2024;51:1891–1908.\n71. Spencer SS. The relative contributions of MRI, SPECT, and PET imaging in epi-", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "596eefe4afd332fb75a93fa99f361f875b1288925be86994ca1a69b52cb298a7"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000094", "text": "appropriate use of PET and SPECT for patients with epilepsy. Eur J Nucl Med\nMol Imaging. 2024;51:1891–1908.\n71. Spencer SS. The relative contributions of MRI, SPECT, and PET imaging in epi-\nlepsy. Epilepsia. 1994;35(suppl 6):S72–S89.\n72. Gok B, Jallo G, Hayeri R, Wahl R, Aygun N. The evaluation of FDG-PET imag-\ning for epileptogenic focus localization in patients with MRI positive and MRI\nnegative temporal lobe epilepsy. Neuroradiology. 2013;55:541–550.\n73. LoPinto-Khoury C, Sperling MR, Skidmore C, et al. Surgical outcome in PET-positive,\nMRI-negative patients with temporal lobe epilepsy. Epilepsia. 2012;53:342–348.\n74. Dupont S, Semah F, Cl\u0001emenceau S, Adam C, Baulac M, Samson Y. Accurate\nprediction of postoperative outcome in mesial temporal lobe epilepsy: a study\nusing positron emission tomography with 18ﬂuorodeoxyglucose. Arch Neurol.\n2000;57:1331–1336.\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n13", "section": "Different commercial and free-access software are currently", "page_from": 13, "page_to": 13, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "f4944777340866402b92e7e209dd3e8e95e675b3c39255edc3f6abf5c87a286f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000095", "text": "75. Vinton AB, Carne R, Hicks RJ, et al. The extent of resection of FDG-PET hypo-\nmetabolism relates to outcome of temporal lobectomy. Brain. 2007;130:548–560.\n76. Tom\u0001as J, Pittau F, Hammers A, et al. The predictive value of hypometabolism in\nfocal epilepsy: a prospective study in surgical candidates. Eur J Nucl Med Mol\nImaging. 2019;46:1806–1816.\n77. Akanuma N, Reed LJ, Marsden PK, et al. Hemisphere-speciﬁc episodic memory\nnetworks in the human brain: a correlation study between intracarotid amobarbital\ntest and [18F]FDG-PET. J Cogn Neurosci. 2009;21:605–622.\n78. Weintrob DL, Saling MM, Berkovic SF, Berlangieri SU, Reutens DC. Verbal\nmemory in left temporal lobe epilepsy: evidence for task-related localization. Ann\nNeurol. 2002;51:442–447.\n79. Benedetti L, Franciotta D, Zoccarato M, et al. Post-therapy normalization of brain\nFDG-PET in Morvan’s syndrome. J Neurol Sci. 2015;353:175–176.\n80. Mauro D, Barbagallo GD, Angelo S, et al. Role of positron emission tomography\nfor central nervous system involvement in systemic autoimmune diseases: status\nand perspectives. Curr Med Chem. 2018;25:3096–3104.\n81. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoim-", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "0f1ce9fee327974b883cd9898ccb258753cd688c03bd50411e3472c94b11a3b0"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000096", "text": "and perspectives. Curr Med Chem. 2018;25:3096–3104.\n81. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoim-\nmune encephalitis. Lancet Neurol. 2016;15:391–404.\n82. Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, et al. The need of\nstandardization and of large clinical studies in an emerging indication of\n[18F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging.\n2017;44:353–357.\n83. Kalra S, Tripathi M, Sonar RS, et al. Role of FDG PET/CT in deﬁnitive and pre-\nsumed autoimmune encephalitis. Nucl Med Commun. 2024;45:121–127.\n84. Liang M, Niu N, Jia C, et al. Diagnostic superiority of 18F-FDG PET over MRI in\ndetecting anti-LGI1 autoimmune encephalitis: a comparative study with insights\ninto faciobrachial dystonic seizures mechanisms and recurrence identiﬁcation.\nClin Nucl Med. 2023;48:e516–e522.\n85. Sadaghiani MS, Roman S, Diaz-Arias LA, et al. Comparison of quantitative\nFDG-PET and MRI in anti-LGI1 autoimmune encephalitis. Neuroradiology.\n2023;65:1225–1238.\n86. Yin Y, Wu J, Wu S, et al. Usefulness of brain FDG PET/CT imaging in pediatric\npatients with suspected autoimmune encephalitis from a prospective study. Eur J", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "4dce36873fcfc006f24362ebd3c12d8eee8bbcc7f6e0cd32b9985de40ed1bdc9"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000097", "text": "2023;65:1225–1238.\n86. Yin Y, Wu J, Wu S, et al. Usefulness of brain FDG PET/CT imaging in pediatric\npatients with suspected autoimmune encephalitis from a prospective study. Eur J\nNucl Med Mol Imaging. 2022;49:1918–1929.\n87. Bordonne M, Chawki MB, Doyen M, et al. Brain 18F-FDG PET for the diagnosis\nof autoimmune encephalitis: a systematic review and a meta-analysis. Eur J Nucl\nMed Mol Imaging. 2021;48:3847–3858.\n88. De Leiris N, Ruel B, Vervandier J, et al. Decrease in the cortex/striatum metabolic\nratio on [18F]-FDG PET: a biomarker of autoimmune encephalitis. Eur J Nucl\nMed Mol Imaging. 2021;49:921–931.\n89. Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI ﬁnd-\nings in autoimmune limbic encephalitis: correlation with autoantibody types.\nJ Neurol. 2013;260:2744–2753.\n90. Morbelli S, Djekidel M, Hesse S, et al. Role of 18F-FDG-PET imaging in the\ndiagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:1009–1010.\n91. Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology\nworking group and European Association for Neuro-Oncology recommendations for\nthe clinical use of PET imaging in gliomas. Neuro-oncol. 2016;18:1199–1208.", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "ae3510e63bffdaa2b7b48624de902bdbc966fbf7a99a4e81f10d5bdf2e632273"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000098", "text": "working group and European Association for Neuro-Oncology recommendations for\nthe clinical use of PET imaging in gliomas. Neuro-oncol. 2016;18:1199–1208.\n92. Prieto E, Mart\u0001ı-Climent JM, Dom\u0001ınguez-Prado I, et al. Voxel-based analysis of\ndual-time-point 18F-FDG PET images for brain tumor identiﬁcation and delinea-\ntion. J Nucl Med. 2011;52:865–872.\n93. Marcus C, Feizi P, Hogg J, et al. Imaging in differentiating cerebral toxoplasmosis and\nprimary CNS lymphoma with special focus on FDG PET/CT. AJR. 2021;216:157–164.\n94. Gupta T, Manjali JJ, Kannan S, Purandare N, Rangarajan V. Diagnostic perfor-\nmance of pretreatment 18F-ﬂuorodeoxyglucose positron emission tomography\nwith or without computed tomography in patients with primary central nervous\nsystem lymphoma: updated systematic review and diagnostic test accuracy meta-\nanalyses. Clin Lymphoma Myeloma Leuk. 2021;21:497–507.\n95. Rozenblum L, Galanaud D, Houillier C, et al. [18F]FDG PET-MRI provides sur-\nvival biomarkers in primary central nervous system lymphoma in the elderly: an\nancillary study from the BLOCAGE trial of the LOC network. Eur J Nucl Med\nMol Imaging. 2023;50:3684–3696.", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "5b93c8d476d09571798dda204a268bd45a52b940177c25cb724010eb1dfcc2d0"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000099", "text": "vival biomarkers in primary central nervous system lymphoma in the elderly: an\nancillary study from the BLOCAGE trial of the LOC network. Eur J Nucl Med\nMol Imaging. 2023;50:3684–3696.\n96. Park HY, Suh CH, Huang RY, Guenette JP, Kim HS. Diagnostic yield of body\nCT and whole-body FDG PET/CT for initial systemic staging in patients with sus-\npected primary CNS lymphoma: a systematic review and meta-analysis. AJR.\n2021;216:1172–1182.\n97. Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y.\nComparison of 11C-methionine PET and 18F-FDG PET in patients with primary\ncentral nervous system lymphoma. Mol Imaging Biol. 2011;13:1284–1289.\n98. Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice\nguidelines/SNMMI procedure standards for imaging of gliomas using PET with\nradiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imag-\ning. 2019;46:540–557.\n99. Colavolpe C, Metellus P, Mancini J, et al. Independent prognostic value of pre-\ntreatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2012;107:527–535.\n100. Colavolpe C, Chinot O, Metellus P, et al. FDG-PET predicts survival in recurrent", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "34bda9d269266dfc2badb96a71ce2635f9fa9ed23383a8411c7284f15bf4ffc6"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000100", "text": "treatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2012;107:527–535.\n100. Colavolpe C, Chinot O, Metellus P, et al. FDG-PET predicts survival in recurrent\nhigh-grade gliomas treated with bevacizumab and irinotecan. Neuro-oncol. 2012;\n14:649–657.\n101. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas\nby PET with ﬂuorine-18-ﬂuorodeoxyglucose and/or carbon-11-methionine.\nJ Nucl Med. 1998;39:778–785.\n102. de Zwart PL, van Dijken BRJ, Holtman GA, et al. Diagnostic accuracy of PET\ntracers for the differentiation of tumor progression from treatment-related changes\nin high-grade glioma: a systematic review and metaanalysis. J Nucl Med. 2020;\n61:498–504.\n103. Pietrzak A, Marszałek A, Kunikowska J, et al. Detection of clinically silent brain\nlesions in [18F]FDG PET/CT study in oncological patients: analysis of over\n10,000 studies. Sci Rep. 2021;11:18293.\n104. Spanaki MV, Siegel H, Kopylev L, et al. The effect of vigabatrin (gamma-\nvinyl GABA) on cerebral blood ﬂow and metabolism. Neurology. 1999;53:\n1518–1522.\n105. Liu S, Wang Y, Xu K, et al. Voxel-based comparison of brain glucose metabo-", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "192cfc3fb6e9c5ad9bfab1fb8ca7bed4cf0ea752056ec3228e0c6c63648bb578"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000101", "text": "vinyl GABA) on cerebral blood ﬂow and metabolism. Neurology. 1999;53:\n1518–1522.\n105. Liu S, Wang Y, Xu K, et al. Voxel-based comparison of brain glucose metabo-\nlism between patients with Cushing’s disease and healthy subjects. Neuroimage\nClin. 2017;17:354–358.\n106. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomo-\ngraphic measurement of local cerebral glucose metabolic rate in humans with\n(F-18)2-ﬂuoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;\n6:371–388.\n107. Jamar F, Buscombe J, Chiti A, et al. EANM/SNMMI guideline for 18F-FDG use\nin inﬂammation and infection. J Nucl Med. 2013;54:647–658.\n108. Clifford AH, Murphy EM, Burrell SC, et al. Positron emission tomography/\ncomputerized tomography in newly diagnosed patients with giant cell arteritis\nwho are taking glucocorticoids. J Rheumatol. 2017;44:1859–1866.\n109. Berman SM, Voytek B, Mandelkern MA, et al. Changes in cerebral glucose\nmetabolism during early abstinence from chronic methamphetamine abuse. Mol\nPsychiatry. 2008;13:897–908.\n110. Volkow ND, Wang GJ, Shokri Kojori E, Fowler JS, Benveniste H, Tomasi D.\nAlcohol decreases baseline brain glucose metabolism more in heavy drinkers than", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2025f4a70d85902e50d7f92c9e1c5b45b630ec484deda34b4573780ff72ef6ee"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000102", "text": "Psychiatry. 2008;13:897–908.\n110. Volkow ND, Wang GJ, Shokri Kojori E, Fowler JS, Benveniste H, Tomasi D.\nAlcohol decreases baseline brain glucose metabolism more in heavy drinkers than\ncontrols but has no effect on stimulation-induced metabolic increases. J Neurosci.\n2015;35:3248–3255.\n111. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on\nNursing Mother Guidelines for the Medical Administration of Radioactive Mate-\nrials. ACMUI website. https://www.nrc.gov/docs/ML1903/ML19038A498.pdf.\nPublished January 31, 2019. Accessed September 18, 2024.\n112. Ishizu K, Nishizawa S, Yonekura Y, et al. Effects of hyperglycemia on FDG\nuptake in human brain and glioma. J Nucl Med. 1994;35:1104–1109.\n113. Sarikaya I, Sarikaya A, Sharma P. Assessing the effect of various blood glucose\nlevels on 18F-FDG activity in the brain, liver, and blood pool. J Nucl Med Tech-\nnol. 2019;47:313–318.\n114. Apostolova I, Lange C, Suppa P, et al. Impact of plasma glucose level on the pat-\ntern of brain FDG uptake and the predictive power of FDG PET in mild cognitive\nimpairment. Eur J Nucl Med Mol Imaging. 2018;45:1417–1422.", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "a09653646d41b72efe4ad4d73bd99fd5bf54f5e82f8bb659ee28e532745b939b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000103", "text": "tern of brain FDG uptake and the predictive power of FDG PET in mild cognitive\nimpairment. Eur J Nucl Med Mol Imaging. 2018;45:1417–1422.\n115. Henriksen OM, Holm S, Marner L, Law I. Effect of blood glucose and body\nweight on image quality in brain [18F]FDG PET imaging. Nucl Med Commun.\n2020;41:1265–1274.\n116. Eskian M, Alavi A, Khorasanizadeh M, et al. Effect of blood glucose level on\nstandardized uptake value (SUV) in 18F-FDG PET-scan: a systematic review and\nmeta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol\nImaging. 2019;46:224–237.\n117. Byun MS, Kim HJ, Yi D, et al. Region-speciﬁc association between basal blood\ninsulin and cerebral glucose metabolism in older adults. Neuroimage Clin. 2019;\n22:101765.\n118. Biessels GJ, Nobili F, Teunissen CE, Sim\u0001o R, Scheltens P. Understanding multi-\nfactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurol.\n2020;19:699–710.\n119. Viglianti BL, Wale DJ, Ma T, et al. Effects of plasma glucose levels on regional\ncerebral 18F-ﬂuorodeoxyglucose uptake: implications for dementia evaluation\nwith brain PET imaging. Biomed Pharmacother. 2019;112:108628.", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "5681039b4582c75f515fb3c496b9b8fe3fda5caa434ddc966abed2de318ae18f"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000104", "text": "cerebral 18F-ﬂuorodeoxyglucose uptake: implications for dementia evaluation\nwith brain PET imaging. Biomed Pharmacother. 2019;112:108628.\n120. Cranston I, Marsden P, Matyka K, et al. Regional differences in cerebral blood\nﬂow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood\nFlow Metab. 1998;18:130–140.\n121. Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose\nblood-brain barrier transport and cerebral metabolism in humans. Diabetes. 1999;\n48:1915–1921.\n122. Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for\nPET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging.\n2009;36:2103–2110.\n123. Lassmann M, Treves ST, Group ESPDHW. Paediatric radiopharmaceutical\nadministration: harmonization of the 2007 EANM paediatric dosage card (version\n14\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "Different commercial and free-access software are currently", "page_from": 14, "page_to": 14, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "2ab4d64c68f966c5f55441c4131a625da3c0e67907b2bbd31e453701291834a6"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000105", "text": "1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med\nMol Imaging. 2014;41:1036–1041.\n124. Treves ST, Gelfand MJ, Fahey FH, Parisi MT. 2016 update of the North Ameri-\ncan Consensus Guidelines for pediatric administered radiopharmaceutical activi-\nties. J Nucl Med. 2016;57:15N–18N.\n125. Rausch I, Ruiz A, Valverde-Pascual I, Cal-Gonz\u0001alez J, Beyer T, Carrio I. Perfor-\nmance evaluation of the Vereos PET/CT system according to the NEMA NU2-\n2012 standard. J Nucl Med. 2019;60:561–567.\n126. Hsu DFC, Ilan E, Peterson WT, Uribe J, Lubberink M, Levin CS. Studies of a\nnext-generation silicon-photomultiplier-based time-of-ﬂight PET/CT system.\nJ Nucl Med. 2017;58:1511–1518.\n127. van Sluis J, de Jong J, Schaar J, et al. Performance characteristics of the digital\nBiograph Vision PET/CT system. J Nucl Med. 2019;60:1031–1036.\n128. van Sluis J, Boellaard R, Somasundaram A, et al. Image quality and semiquantita-\ntive measurements on the Biograph Vision PET/CT system: initial experiences\nand comparison with the Biograph mCT. J Nucl Med. 2020;61:129–135.\n129. Chen S, Hu P, Gu Y, Yu H, Shi H. Performance characteristics of the digital", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "8c6b0a54b9338d337cf8967a46d3e1792ba74a080a7890c051b3fb8eb87f47b2"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000106", "text": "and comparison with the Biograph mCT. J Nucl Med. 2020;61:129–135.\n129. Chen S, Hu P, Gu Y, Yu H, Shi H. Performance characteristics of the digital\nuMI550 PET/CT system according to the NEMA NU2-2018 standard. EJNMMI\nPhys. 2020;7:43.\n130. Salvadori J, Imbert L, Perrin M, et al. Head-to-head comparison of image quality\nbetween brain. EJNMMI Res. 2019;9:61.\n131. Rausch I, Quick HH, Cal-Gonzalez J, Sattler B, Boellaard R, Beyer T. Technical\nand instrumentational foundations of PET/MRI. Eur J Radiol. 2017;94:A3–A13.\n132. Chen Y, Ying C, Binkley MM, et al. Deep learning-based T1-enhanced selection\nof linear attenuation coefﬁcients (DL-TESLA) for PET/MR attenuation correction\nin dementia neuroimaging. Magn Reson Med. 2021;86:499–513.\n133. Mecheter I, Alic L, Abbod M, Amira A, Ji JMR. Image-based attenuation correc-\ntion of brain PET imaging: review of literature on machine learning approaches\nfor segmentation. J Digit Imaging. 2020;33:1224–1241.\n134. Hofmann M, Pichler B, Sch€olkopf B, Beyer T. Towards quantitative PET/MRI: a\nreview of MR-based attenuation correction techniques. Eur J Nucl Med Mol\nImaging. 2009;36(suppl 1):S93–S104.", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "4c16e0a4146ea02eb044ba1177182a05a4eb58389aea5c44ac48bca2616042e2"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000107", "text": "134. Hofmann M, Pichler B, Sch€olkopf B, Beyer T. Towards quantitative PET/MRI: a\nreview of MR-based attenuation correction techniques. Eur J Nucl Med Mol\nImaging. 2009;36(suppl 1):S93–S104.\n135. De Luca F, Bolin M, Blomqvist L, Wassberg C, Martin H, Falk Delgado A. Vali-\ndation of PET/MRI attenuation correction methodology in the study of brain\ntumours. BMC Med Imaging. 2020;20:126.\n136. Ladefoged CN, Hansen AE, Henriksen OM, et al. AI-driven attenuation correc-\ntion for brain PET/MRI: clinical evaluation of a dementia cohort and importance\nof the training group size. Neuroimage. 2020;222:117221.\n137. Ladefoged CN, Law I, Anazodo U, et al. A multi-centre evaluation of eleven clin-\nically feasible brain PET/MRI attenuation correction techniques using a large\ncohort of patients. Neuroimage. 2017;147:346–359.\n138. Ladefoged CN, Andersen FL, Kjær A, Højgaard L, Law I. RESOLUTE\nPET/MRI attenuation correction for O-(2-18F-ﬂuoroethyl)-L-tyrosine (FET) in\nbrain tumor patients with metal implants. Front Neurosci. 2017;11:453.\n139. Chang LT. A method for attenuation correction in radionuclide computed tomog-\nraphy. IEEE Trans Nucl Sci. 1978;25:638–643.", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "b6a507b9dd0d7afc84a5fedd4e90d2713233d50e6e27b7e1fd91306e7c279951"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000108", "text": "brain tumor patients with metal implants. Front Neurosci. 2017;11:453.\n139. Chang LT. A method for attenuation correction in radionuclide computed tomog-\nraphy. IEEE Trans Nucl Sci. 1978;25:638–643.\n140. Chen WP, Matsunari I, Noda A, et al. Rapid scanning protocol for brain 18F-FDG\nPET: a validation study. J Nucl Med. 2005;46:1633–1641.\n141. Verger A, Guedj E. The renaissance of functional F-18-FDG PET brain activation\nimaging. Eur J Nucl Med Mol Imaging. 2018;45:2338–2341.\n142. Rousseau PF, Malbos E, Verger A, et al. Increase of precuneus metabolism corre-\nlates with reduction of PTSD symptoms after EMDR therapy in military veterans:\nan 18F-FDG PET study during virtual reality exposure to war. Eur J Nucl Med\nMol Imaging. 2019;46:1817–1821.\n143. Verger A, Malbos E, Reynaud E, et al. Brain metabolism and related connectivity\nin patients with acrophobia treated by virtual reality therapy: an 18F-FDG PET\npilot study sensitized by virtual exposure. EJNMMI Res. 2018;8:93.\n144. Cardier M, Zulueta-Santos C, Manrique-Huarte R, et al. Functional neuroim-\naging studies in asymmetric hearing loss. Audiol Neurootol. 2015;20(suppl 1):\n48–52.", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "6f53bf2fee5768a529ed15df8db1389d1ca07d583461e9b4d4cb0069e3ddbca1"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000109", "text": "144. Cardier M, Zulueta-Santos C, Manrique-Huarte R, et al. Functional neuroim-\naging studies in asymmetric hearing loss. Audiol Neurootol. 2015;20(suppl 1):\n48–52.\n145. Schreckenberger M, Spetzger U, Sabri O, et al. Localisation of motor areas in\nbrain tumour patients: a comparison of preoperative [18F]FDG-PET and intrao-\nperative cortical electrostimulation. Eur J Nucl Med. 2001;28:1394–1403.\n146. Herholz K, Pietrzyk U, Karbe H, W€urker M, Wienhard K, Heiss WD. Individual\nmetabolic anatomy of repeating words demonstrated by MRI-guided positron\nemission tomography. Neurosci Lett. 1994;182:47–50.\n147. Villien M, Wey HY, Mandeville JB, et al. Dynamic functional imaging of brain\nglucose utilization using fPET-FDG. Neuroimage. 2014;100:192–199.\n148. Tsutsui Y, Awamoto S, Himuro K, Umezu Y, Baba S, Sasaki M. Edge artifacts in\npoint spread function-based PET reconstruction in relation to object size and\nreconstruction parameters. Asia Ocean J Nucl Med Biol. 2017;5:134–143.\n149. Matti A, Lima GM, Pettinato C, Pietrobon F, Martinelli F, Fanti S. How do the\nmore recent reconstruction algorithms affect the interpretation criteria of PET/CT\nimages? Nucl Med Mol Imaging. 2019;53:216–222.", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "00ea16c8154f71ca5929accce254aa86bd9423a514fc4ef2606bc615ea3bccf6"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000110", "text": "more recent reconstruction algorithms affect the interpretation criteria of PET/CT\nimages? Nucl Med Mol Imaging. 2019;53:216–222.\n150. PET acquisition. ADNI website. https://adni.loni.usc.edu/data-samples/adni-data/\nneuroimaging/pet/.\n151. SCAN website. https://scan.naccdata.org/.\n152. Verwer EE, Golla SSV, Kaalep A, et al. Harmonisation of PET/CT contrast recovery\nperformance for brain studies. Eur J Nucl Med Mol Imaging. 2021;48:2856–2870.\n153. Brain PET/CT Accreditation. EARL website. https://earl.eanm.org/18f-brain-pet-ct/.\n154. Herholz K. Guidance for reading FDG PET scans in dementia patients. Q J Nucl\nMed Mol Imaging. 2014;58:332–343.\n155. Ohnishi T, Hoshi H, Nagamachi S, et al. High-resolution SPECT to assess\nhippocampal perfusion in neuropsychiatric diseases. J Nucl Med. 1995;36:1163–\n1169.\n156. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer’s Disease Neuroimaging\nInitiative (ADNI): clinical characterization. Neurology. 2010;74:201–209.\n157. Caminiti SP, Sala A, Presotto L, et al. Validation of FDG-PET datasets of normal\ncontrols for the extraction of SPM-based brain metabolism maps. Eur J Nucl Med\nMol Imaging. 2021;48:2486–2499.", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "7b7e762017d690960c07aa25c4eb14c64e7ac663119f5e728e2b2c339dd35441"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000111", "text": "157. Caminiti SP, Sala A, Presotto L, et al. Validation of FDG-PET datasets of normal\ncontrols for the extraction of SPM-based brain metabolism maps. Eur J Nucl Med\nMol Imaging. 2021;48:2486–2499.\n158. Thomas BA, Erlandsson K, Modat M, et al. The importance of appropriate partial\nvolume correction for PET quantiﬁcation in Alzheimer’s disease. Eur J Nucl Med\nMol Imaging. 2011;38:1104–1119.\n159. Yang J, Hu C, Guo N, et al. Partial volume correction for PET quantiﬁcation and\nits impact on brain network in Alzheimer’s disease. Sci Rep. 2017;7:13035.\n160. L\u0001opez-Gonz\u0001alez FJ, Silva-Rodr\u0001ıguez J, Paredes-Pacheco J, et al. Intensity nor-\nmalization methods in brain FDG-PET quantiﬁcation. Neuroimage. 2020;222:\n117229.\n161. Mortensen KN, Gjedde A, Thompson GJ, et al. Impact of global mean normaliza-\ntion on regional glucose metabolism in the human brain. Neural Plast. 2018;\n2018:6120925.\n162. Borghammer P, Jonsdottir KY, Cumming P, et al. Normalization in PET group\ncomparison studies–the importance of a valid reference region. Neuroimage.\n2008;40:529–540.\n163. Borghammer P. Perfusion and metabolism imaging studies in Parkinson’s disease.\nDan Med J. 2012;59:B4466.", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "de17d56e02ae88bcc4a79e99fd95801dc6f9b8809ed6fb83ea73aebe7fac9165"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000112", "text": "2008;40:529–540.\n163. Borghammer P. Perfusion and metabolism imaging studies in Parkinson’s disease.\nDan Med J. 2012;59:B4466.\n164. Yakushev I, Landvogt C, Buchholz HG, et al. Choice of reference area in studies\nof Alzheimer’s disease using positron emission tomography with ﬂuorodeoxyglu-\ncose-F18. Psychiatry Res. 2008;164:143–153.\n165. Zhang H, Wu P, Ziegler SI, et al. Data-driven identiﬁcation of intensity nor-\nmalization region based on longitudinal coherency of. Neuroimage. 2017;\n146:589–599.\n166. Morbelli S, Arbizu J, Booij J, et al. The need of standardization and of large clinical\nstudies in an emerging indication of. Eur J Nucl Med Mol Imaging. 2017;44:353–357.\n167. Drzezga A, Arnold S, Minoshima S, et al. 18F-FDG PET studies in patients with\nextratemporal and temporal epilepsy: evaluation of an observer-independent anal-\nysis. J Nucl Med. 1999;40:737–746.\n168. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach\nin Alzheimer’s disease using three-dimensional stereotactic surface projections of\nﬂuorine-18-FDG PET. J Nucl Med. 1995;36:1238–1248.\n169. Perovnik M, Rus T, Schindlbeck KA, Eidelberg D. Functional brain networks in", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "185e2699b6f4d710339190adff57d18a34fd4cd60406436fcc826961c3433ae8"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000113", "text": "ﬂuorine-18-FDG PET. J Nucl Med. 1995;36:1238–1248.\n169. Perovnik M, Rus T, Schindlbeck KA, Eidelberg D. Functional brain networks in\nthe evaluation of patients with neurodegenerative disorders. Nat Rev Neurol.\n2023;19:73–90.\n170. Spetsieris PG, Eidelberg D. Scaled subproﬁle modeling of resting state imaging\ndata in Parkinson’s disease: methodological issues. Neuroimage. 2011;54:2899–\n2914.\n171. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging\nusing ﬂuorine-18-FDG. Society of Nuclear Medicine. J Nucl Med. 1998;39:\n1302–1305.\n172. Phelps ME. PET: the merging of biology and imaging into molecular imaging.\nJ Nucl Med. 2000;41:661–681.\n173. Lucignani G, Schmidt KC, Moresco RM, et al. Measurement of regional cere-\nbral glucose utilization with ﬂuorine-18-FDG and PET in heterogeneous tis-\nsues: theoretical considerations and practical procedure. J Nucl Med. 1993;\n34:360–369.\n174. Henry TR, Engel J, Mazziotta JC. Clinical evaluation of interictal ﬂuorine-18-\nﬂuorodeoxyglucose PET in partial epilepsy. J Nucl Med. 1993;34:1892–1898.\n175. Palard-Novello X, Visser D, Tolboom N, et al. Validation of image-derived input", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "ea3d5179efed467d25ea1e320214dc3770affd84fbb53e736cf3916a5e88b825"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000114", "text": "ﬂuorodeoxyglucose PET in partial epilepsy. J Nucl Med. 1993;34:1892–1898.\n175. Palard-Novello X, Visser D, Tolboom N, et al. Validation of image-derived input\nfunction using a long axial ﬁeld of view PET/CT scanner for two different tracers.\nEJNMMI Phys. 2024;11:25.\n176. Graham MM, Muzi M, Spence AM, et al. The FDG lumped constant in normal\nhuman brain. J Nucl Med. 2002;43:1157–1166.\n177. Hasselbalch SG, Madsen PL, Knudsen GM, Holm S, Paulson OB. Calculation of\nthe FDG lumped constant by simultaneous measurements of global glucose and\nFDG metabolism in humans. J Cereb Blood Flow Metab. 1998;18:154–160.\n178. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malig-\nnant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: anal-\nysis of the FDG lumped constant. J Nucl Med. 1998;39:440–448.\nPROCEDURE STANDARD\n\u0001\nArbizu et al.\n15", "section": "Different commercial and free-access software are currently", "page_from": 15, "page_to": 15, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "0f3c15c077179f2130acb31409b0aadd64ebff3b5cdb45eaa3acc53a3ab802cd"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000115", "text": "179. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF. Brain\nmetabolism during fasting. J Clin Invest. 1967;46:1589–1595.\n180. Redies C, Hoffer LJ, Beil C, et al. Generalized decrease in brain glucose metabolism\nduring fasting in humans studied by PET. Am J Physiol. 1989;256:E805–E810.\n181. Cecchin D, Garibotto V, Law I, Gofﬁn K. PET imaging in neurodegeneration and\nneuro-oncology: variants and pitfalls. Semin Nucl Med. 2021;51:408–418.\n182. Kono AK, Ishii K, Sofue K, Miyamoto N, Sakamoto S, Mori E. Fully automatic dif-\nferential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease\nusing FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2007;34:1490–1497.\n183. Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE. Alzheimer dis-\nease: improved visual interpretation of PET images by using three-dimensional\nstereotaxic surface projections. Radiology. 1996;198:837–843.\n184. Lehman VT, Carter RE, Claassen DO, et al. Visual assessment versus quantitative\nthree-dimensional stereotactic surface projection ﬂuorodeoxyglucose positron\nemission tomography for detection of mild cognitive impairment and Alzheimer\ndisease. Clin Nucl Med. 2012;37:721–726.", "section": "Different commercial and free-access software are currently", "page_from": 16, "page_to": 16, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "11cc10e21d8788dd379a0b5c3e1f73a5ea6abc3d4e033551c45990aa6a8fd13b"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000116", "text": "three-dimensional stereotactic surface projection ﬂuorodeoxyglucose positron\nemission tomography for detection of mild cognitive impairment and Alzheimer\ndisease. Clin Nucl Med. 2012;37:721–726.\n185. Morbelli S, Brugnolo A, Bossert I, et al. Visual versus semi-quantitative analysis\nof 18F-FDG-PET in amnestic MCI: an European Alzheimer’s Disease Consortium\n(EADC) project. J Alzheimers Dis. 2015;44:815–826.\n186. Perani D, Della Rosa PA, Cerami C, et al. Validation of an optimized SPM proce-\ndure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin.\n2014;6:445–454.\n187. Frisoni GB, Bocchetta M, Ch\u0001etelat G, et al. Imaging markers for Alzheimer dis-\nease: which vs how. Neurology. 2013;81:487–500.\n188. Signorini M, Paulesu E, Friston K, et al. Rapid assessment of regional cerebral\nmetabolic abnormalities in single subjects with quantitative and nonquantitative\n[18F]FDG PET: A clinical validation of statistical parametric mapping. Neuro-\nimage. 1999;9:63–80.\n189. Ishii K, Kono AK, Sasaki H, et al. Fully automatic diagnostic system for early-\nand late-onset mild Alzheimer’s disease using FDG PET and 3D-SSP. Eur J Nucl\nMed Mol Imaging. 2006;33:575–583.", "section": "Different commercial and free-access software are currently", "page_from": 16, "page_to": 16, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "5ee38978399240780f0939d62f5662b938b335e36954a6bdd30f9c4aff5fadf9"}
{"doc_id": "snmmi__v00000000", "chunk_id": "000117", "text": "189. Ishii K, Kono AK, Sasaki H, et al. Fully automatic diagnostic system for early-\nand late-onset mild Alzheimer’s disease using FDG PET and 3D-SSP. Eur J Nucl\nMed Mol Imaging. 2006;33:575–583.\n190. Wagatsuma K, Sakata M, Ishibashi K, et al. Direct comparison of brain [18F]FDG\nimages acquired by SiPM-based and PMT-based PET/CT: phantom and clinical\nstudies. EJNMMI Phys. 2020;7:70.\n191. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative\npitfalls in PET imaging with 18-ﬂuoro-2-deoxyglucose and carbon-11 methio-\nnine. Eur J Nucl Med. 1999;26:1363–1378.\n192. Ruotsalainen U, Suhonen-Polvi H, Eronen E, et al. Estimated radiation dose to\nthe newborn in FDG-PET studies. J Nucl Med. 1996;37:387–393.\n193. Wu TH, Huang YH, Lee JJ, Wang SY, Wang SC, Su CT, et al. Radiation exposure\nduring transmission measurements: comparison between CT- and germanium-\nbased techniques with a current PET scanner. Eur J Nucl Med Mol Imaging. 2004;\n31:38–43.\n16\nTHE JOURNAL OF NUCLEAR MEDICINE\n\u0001 Vol. 00\n\u0001 No. 00\n\u0001 XXX 2024", "section": "Different commercial and free-access software are currently", "page_from": 16, "page_to": 16, "display_name": "SNMMI", "version": "v00000000", "created_at": "2025-11-28T06:05:57", "hash": "8311bc23ef61f0b2ebe50eb6c56945acc0206ce31ea2eaa27f0abaff419df50d"}
